Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808558], Inc.  CONFIDENTIAL  Page 1 of 62 Phase 1/2 Dose -Rising, Safety , Tolerability and Efficacy 
Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Metastases  
 
Protocol Identifying Number:  SOR007 -2017 -01 
 Principal Investigator:
  [INVESTIGATOR_609898], MD, FACS .  
University of Southern [LOCATION_004]  
[ADDRESS_808559]  
Los Angeles, CA [ZIP_CODE]  
 
IND Sponsor:     NanOlogy , LLC  
[ADDRESS_808560]  
San Luis Obispo, CA [ZIP_CODE]- 7310 
 
Version Number:     7.0 
 Date:      28 December 2018  
 
        
 
 
  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808561] OF ABBREVIATIONS  ....................................................................................................................................... 5 
SPONSOR SIGNATURE [CONTACT_1783]  ............................................................................................................................... 7 
STATEM ENT OF COMPLIANCE  ............................................................................................................................. 8 
PROTOCOL SUMMARY  ........................................................................................................................................... 9 
SCHEMATIC OF STUDY DESIGN  ........................................................................................................................ 12 
1 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ...................... 13 
1.1 Background Information  .................................................................................................................... 13 
1.2 Rationale  ............................................................................................................................................. 15 
1.3 Potential Risks and Benefits  ............................................................................................................ 16 
1.3.1  Known Potential Risks  ................................................................................................... 16 
1.3.2  Known Potential Benefits  .............................................................................................. 16 
2 OBJECTIVES AND PURPOSE  .................................................................................................................. 17 
3 STUDY DESIGN AND ENDPOINTS  ......................................................................................................... 17 
3.1 Description of the Study Design  ...................................................................................................... 17 
3.2 Primary Endpoint  ............................................................................................................................... 18 
3.3 Secondary Endpoints  ........................................................................................................................ 18 
3.4 Exploratory Endpoints  ....................................................................................................................... 19 
4 STUDY ENROLLMENT AND WITHDRAWAL  ......................................................................................... 19 
4.1 Participant Inclusion Criteria ............................................................................................................ 19 
4.2 Participant Exclusion Criteria ........................................................................................................... 20 
4.3 Strategies for Recruitment and Retention  ...................................................................................... 20 
4.4 Participant Withdrawal or termination  ............................................................................................. 21 
4.4.1  Reasons for Withdrawal or Termination  ..................................................................... 21 
4.4.2  Handling of Participant Withdrawals or Termination  ................................................. 21 
4.5 Premature Termination or Suspension of Study  ........................................................................... 22 
5 STUDY DRUG  .............................................................................................................................................. 22 
5.1 Study Drug(s) Description  ................................................................................................................ [ADDRESS_808562] Storage and Stability  ....................................................................................... 23 
5.1.4  Preparation  ...................................................................................................................... 23 
5.1.5  Dosing and Administration  ............................................................................................ 23 
5.1.6  Route of Administration  .................................................................................................  24 
5.1.7  Dosing and Dose Escalation ........................................................................................ 24 
5.1.8  Dose Adjustments/Modifications/Delays  .................................................................... 24 
5.1.9  Duration of Treatment  ................................................................................................... 24 
5.1.10  Dosing Compliance  ........................................................................................................ 24 
5.2 Study Drug Accountability Procedures  ........................................................................................... 25 
6 STUDY PROCEDURES AND SCHEDULE  .............................................................................................. 25 
6.1 Study Procedures/Evaluations  ......................................................................................................... [ADDRESS_808563] of Care Study Procedures  ........................................................................... 26 
6.2 Treatment Area Selection  ................................................................................................................. 27 
6.3 Photographic Documentation ........................................................................................................... 27 
6.4 Laboratory Procedures/Evaluations  ................................................................................................ 27 
6.4.1  Clinical Laboratory Evaluations  .................................................................................... 27 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808564], Inc.  CONFIDENTIAL  Page 3 of 62 6.4.2  Other Assays or Procedures  ........................................................................................ 28 
6.5 Study Schedule  .................................................................................................................................. 28 
6.5.1  Screening  ........................................................................................................................ 28 
6.5.2  Enrollment/Baseline  ....................................................................................................... 29 
6.5.3  Treatment  ........................................................................................................................ 30 
6.5.4  Follow up and End- of-Study Evaluations: Group A ................................................... 33 
6.5.5  Follow up and End- of-Study Evaluations: Group B ................................................... 33 
6.5.6  Early Termination Visit  .................................................................................................. 34 
6.5.7  UNSCHEDULED VISIT  .................................................................................................  34 
6.5.8  Schedule of Events Table 1: Treatment Group A: 28 Days  ..................................... 35 
6.5.9  Schedule of Events Table 2: Treatment Group B: 56 Days  ..................................... 37 
6.6 Concomitant Medications, Treatments, and Procedures  ............................................................. 39 
6.6.1  Precautionary Medications, Treatments, and Procedures  ....................................... 39 
6.6.2  Prohibited Medications, Treatments, and Procedures  ............................................. 39 
6.6.3  Prophylactic Medications, Treatments, and Procedures  .......................................... 39 
7 ASSESSMENT OF SAFETY  ...................................................................................................................... 40 
7.1 Specification of Safety Parameters  .................................................................................................  40 
7.1.1  Definition of Adverse Events (AE) and Adverse Drug Reaction (ADR)  ................. 40 
7.1.2  Definition of Serious Adverse Events (SAE)  .............................................................. [ADDRESS_808565]  ............................................................................................. 45 
7.4.4  Reporting of Pregnancy  ................................................................................................ 45 
7.5 Study Halting Rules  ........................................................................................................................... 45 
7.6 Dose Escalation and Dose Limiting Toxicity  .................................................................................. 46 
7.7 Safety Oversight  ................................................................................................................................ 48 
8 CLINICAL MONITORING ............................................................................................................................ 48 
9 STATISTICAL CONSIDERATIONS .......................................................................................................... 49 
9.1 Statistical and Analytical Plans  ........................................................................................................ 49 
9.2 Statistical Hypotheses  ....................................................................................................................... 49 
9.3 Analysis Datasets  .............................................................................................................................. 49 
9.3.1  Missing Data  ................................................................................................................... 49 
9.4 Description of Statistical Methods  ................................................................................................... 49 
9.4.1  General Approach  .......................................................................................................... 49 
9.4.2  Analysis of the Primary Efficacy Endpoint(s)  ............................................................. 49 
9.4.3  Analysis of the Secondary Endpoint(s)  ....................................................................... 49 
9.4.4  Safety Analyses  .............................................................................................................. 50 
9.4.5  Adherence and Retention Analyses  ............................................................................ 51 
9.4.6  Baseline Descriptive Statistics  ..................................................................................... 51 
9.4.7  Planned Interim Analyses  ............................................................................................. 51 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808566], Inc.  CONFIDENTIAL  Page 4 of 62 9.4.8  Multiple Comparison/Multiplicity ................................................................................... 52 
9.4.9  Tabulation of Individual Response Data  ..................................................................... 52 
9.4.10  Concomitant Medication ................................................................................................ 52 
9.5 Safety Monitoring Committee (SMC)  .............................................................................................. 52 
9.6 Sample Size  ....................................................................................................................................... 52 
9.7 Measures to Minimize Bias  .............................................................................................................. 53 
9.7.1  Enrollment/ Randomization/ Masking Procedures  .................................................... 53 
9.7.2  Evaluation of Success of Blinding  ............................................................................... 53 
9.7.3  Breaking the Study Blind/Participant Code  ................................................................ 53 
10 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ................................... 53 
11 QUALITY ASSURANCE AND QUALITY CONTROL  .............................................................................. 54 
12 ETHICS/PROTECTION OF HUMAN SUBJECTS  ................................................................................... [ADDRESS_808567] POLICY  .......................................................................................................... 60 
16 LIABILITY AND INSURANCE  .................................................................................................................... 61 
17 LITERATURE REFERENCES .................................................................................................................... 61 
 
  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808568]  Aspartate Aminotransferase  
BID ‘Bis in Die’ or Twice per Day  
BUN  Blood Urea Nitrogen  
CFR  Code of Federal Regulations  
CLIA  Clinical Laboratory Improvement Amendments  
CNS  Central Nervous System  
CTCAE  Common Terminology Criteria for Adverse Events  
ECOG  Eastern Cooperative Oncology Group  
EDC  Electronic Data Capture System  
eCRF  Electronic Case Report Form  
FDA  The U.S. Food and Drug Administration  
FTU  Finger Tip Unit  
GCP  Good Clinical Practice  
GGT  Gamma -Glutamyl Transferase  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council for Harmonization  of Technical Requirements for 
Pharmaceuticals for Human Use  
ICMJE  International Committee of Medical Journal Editors  
IND Investigational New Drug Application  
IP Intraperitoneal  
IRB Institutional Review Board  
IV Intravenous  
MCH  Mean Corpuscular Hemoglobin  
MCHC  Mean Corpuscular Hemoglobin Concentration  
MCV  Mean Corpuscular Volume  
MTD  Maximum Tolerated Dose  
NCI National Cancer Institute  
NDA  New Drug Application  
NIH National Institutes of Health  
NRS -[ADDRESS_808569]  Response Evaluation Criteria in Solid Tumours  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808570] of Care  
TEAE  Treatment -emergent Adverse Event  
USC  University of Southern [LOCATION_004]  
USP/NF  [LOCATION_002] Pharmacopeia/National Formulary  
WBC  White Blood Cell  
  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808571] read the attached protocol (SOR007- 2017- 01) Phase 1/ [ADDRESS_808572] the confidentiality of the document. 
The signature [CONTACT_114117] [INVESTIGATOR_411194]/her agreement. 
 
 
__________________________________________ __________________________ 
Signature [CONTACT_789]     [CONTACT_1782]  
 
 __________________________________________ 
Printed Name [CONTACT_789]  
  
[CONTACT_7609] 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808573], Inc.  CONFIDENTIAL  Page 9 of 62 PROTOCOL SUMMARY 
Protocol #:  SOR007- 2017- 01 
Title:  Phase 1/2 Dose -Rising, Safety , Tolerability  and Efficacy Study of Topi[INVESTIGATOR_609899]007 for Cutaneous Metastases.  
Summary:  This is a P hase 1/2, open- label, dose -rising study evaluating the safety , 
tolerability  and preliminary efficacy of three  concentrations of SOR007 
(Uncoated Nanoparticle Paclitaxel) Ointment  (0.15%, 1.0%, and 2.0%) 
applied topi[INVESTIGATOR_577724] [ADDRESS_808574] (version 1.1) definition of measurable tumors  (≥ 10mm in its 
longest diameter ). Using a gloved hand, s ubjects will apply one Finger  Tip 
Unit (FTU) of SOR007 to the  50 cm2 treatment area twice daily at 
approximately the same time each day for 28  to up to 56 days. Subjects 
will attend the clinic on Day 1 ( Visit 2 ) for dose application training and 
observation of the first treatment appl ication , returning 24 hours later for 
pharmacokinetic sample collection . Additional visits will be on Days  8, 
15, 29, and 43 for 28 treatment days, or on Days 8, 15, 29, 57 and 70 for 
56 treatment days . The final visit will be completed by [CONTACT_609923] (per Investigator determination), > [ADDRESS_808575] two  global and two 
close- up color photographs of the treatment area will be taken  (with a ruler 
for scale)  by [CONTACT_737] . The photographs  will be uploaded from each 
visit to a secure, password protected Citrix ShareFile or site restricted -
access file, within 2 days of the visit. The Sponsor will then analyze lesion size using Ima geJ. 
The s tudy will include a  dose escalation  phase  and a dose expansion phase .  
Dose Escalation Phase:  
During the dose  escalation phase , the study  will follow a standard 3+[ADDRESS_808576] cohort of three subjects commencing 
treatment  with 0.15% SOR007. A Safety Monitoring Committee (SMC) 
will review all available data after  the last subject in  each cohort of three 
subjects completes 15 days of treatment to determine whether dose 
escalation may continue. If a single dose limiting t oxicity (DLT) is 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808577], Inc.  CONFIDENTIAL  Page 10 of 62 identified in one of three  subjects in the cohort, a further three  subjects will 
be enrolled at the same dose level. If one  or more  DLT occur  in the three  
additional  subjects enrolled in the cohort, dose escalation will stop and the 
prior dose level will be regarded as the Maximum Tolerated Dose (MTD) 
and taken forward into the dose expansion phase. If no further DLT are identified, dose escalation will continue, unti l either a DLT is identified at 
a higher dose or the top dose of 2.0%  SOR007 is reached.  
Dose Expansion Phase:  
In the dose  expansion phase, additional subject s will be enrolled to reach 
a maximum of 16 total subjects at the MTD from  the dose  escalation phase . 
Subjects in the dose expansion phase will attend the clinic on the same 
visit days  and receive the same evaluations  as the dose escalation phase 
above. The option of 28 (Group A) or 56 (Group B) days of treatment will 
be per investigatior d ecision, dependent on subject disease progression, 
additional systemic chemotherapy or other metastatic treatment 
requirements.  
Objectives:  
 Primary Objective:  
• To determine preliminary safety and tolerability of topi[INVESTIGATOR_609899]007. 
Secondary Objectives : 
• To determine preliminary efficacy of topi[INVESTIGATOR_609897]007 ;  
• To study potential r eduction in pain at the treatment area;  
• To describe the pharmacokinetics of topi[INVESTIGATOR_609897]007 Ointment 
applied to metastatic  lesions . 
Endpoint  Primary Outcome Measures : 
Safety and tolerability, as demonstrated by [CONTACT_20721] , changes in 
laboratory assessments, physical examination findings, and vital signs.  
Secondary Outcome Measures : 
Efficacy will be determined by [CONTACT_609924] (s) in the treatment area betwe en baseline and Day 43 or 70 using a 
calibrated grid measurement system ( ImageJ freeware)  provided by [CONTACT_4878]  (NIH) . Eligible lesions will be determined at 
baseline by [CONTACT_39694] (Vn 1.1) definition of measurable tumors (≥ 10mm in  its longest diameter) (Eisenhauer 2009).  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808578], Inc.  CONFIDENTIAL  Page 11 of 62 Objective Clinical Response  (Complete Clinical Response (CR) + Partial 
Response (PR)) is defined as the percentage of patients who achieve 
complete clinical response or partial response [ADDRESS_808579] response recorded from the 
start of study treatment until the end of treatment.  
Reduction in pain at the treatment area will be measured by [CONTACT_609925] (NRS -11) from baseline to Day 43 or 70. 
Systemic Exposure as determined by: T max, Cmax, AUC  
Pharmacokinetics (PK)  Blood samples will be collected to analyze pharmacokinetic activity . 
Samples will be collected at 24 hours (+/ - 2 hour s) after the first study 
drug application.  
28 Days of Treatment: A t Visits 3 and 4  (prior to the first daily 
application ) and at  Visits 5 and 6 (a t any time during the visit) . 
56 Days of Treatment : At Visits 3, 4 and 5 ( prior to the first daily 
application ) and at  Visits 6 and 7 ( at any time during  the visit) .  
Population:  A minimum of t hree up to a maximum of 28 male and female subjects , ≥ 
18 years of age, with non -melanoma cutaneous metastases.  
Phase:  1/2 
Number of Sites : Up to four  
Description of Study Agent:  SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment (SOR007) at 
concentrations of 0.15%, 1.0%, and 2.0%.  
Study Duration:  The study duration is estimated to take [ADDRESS_808580]’s  last visit.  
Participant Duration:  Individual subject par ticipation is estimated  to be  75 or 102 days, including 
the screening period.  
 
  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808581], Inc.  CONFIDENTIAL  Page 12 of 62 SCHEMATIC OF STUDY DESI GN 
Figure 1. Dose Escalation Algorithm – Flow Chart  
 

Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808582], Inc.  CONFIDENTIAL  Page 13 of 62 1 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE  
1.[ADDRESS_808583] to IND 135896; in accordance with [ADDRESS_808584] SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment (SOR007) is being developed for the topi[INVESTIGATOR_609900] . SOR007 consists of Uncoated 
Nanoparticle Paclitaxel suspended in an ointment vehicle. All excipi[INVESTIGATOR_609901] 
(USP/NF ) and approved for topi[INVESTIGATOR_609902].  
SOR007 is also being investigated under IND 126915 for the treatment of moderate to severe 
plaque psoriasis and actinic keratosis (Sponsor: DFB Soria, LLC). NanoPac® (sterile nanoparticulate paclitaxel) Powder for Suspension (“NanoPac”) contains the same nanoparticulate 
paclitaxel as SOR007, although the nanoparticulate paclitaxel in NanoPac is sterile (Sponsor: NanOlogy, LLC). NanoPac is being developed for the treatment of peritoneal malignancies under IND 073529, the treatment of pancreatic neoplasms under IND 132692, and the treatment of adenocarcinoma of the prostate under IND 132694.  
Non-clinical Summary  
Key findings of nonclinical studies with nanoparticulate paclitaxel include:  
• In vitro  dermal penetration studies using human cadaver skin and the Franz diffusion c ell 
system were conducted with prototype gel and ointment formulations of Uncoated Nanoparticle Paclitaxel to evaluate the rate and extent of in vitro dermal and transdermal delivery of paclitaxel. In the first study, three 1% Uncoated Nanoparticle Paclita xel gels 
(designated as DowF1 through DowF3) and four 1% Uncoated Nanoparticle Paclitaxel 
ointments (designated as DowF4 through DowF7) were evaluated. In the second study, one 
0.5% (designated as DowF8), four 1% (designated as DowF10 through DowF13), and one 2% (designated as DowF9) Uncoated Nanoparticle Paclitaxel ointments were tested, along with a second lot of 1% Uncoated Nanoparticle Paclitaxel ointment (designated DowF6 
formulation). There was negligible transdermal flux of paclitaxel in the first or  second 
study. In the first study, DowF6 (1% SOR007 Ointment) demonstrated the highest total 
epi[INVESTIGATOR_3915]/dermal delivery (2.2% of the applied dose). In the second study, DowF8 (0.5% SOR007 Ointment) delivered 4.5% of the applied dose to the epi[INVESTIGATOR_609903]. 
 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808585], Inc.  CONFIDENTIAL  Page 14 of 62 • Paclitaxel toxicokinetics were determined on Days 1 and 28 following once -daily topi[INVESTIGATOR_536057] 0% (0 mg/kg/day) 0.3% (4.9 mg/kg/day), 1% (16.5 mg/kg/day) or 3% 
(49.9 mg/kg/day) SOR007 to the dorsum of 6 Göttingen minipi[INVESTIGATOR_14107]/sex/group. Sex 
differences in paclitaxel mean C max and AUC 0-24 values were generally less than 2 -fold; 
therefore, results and discussions were based on combined- sex data. Exposure to paclitaxel 
increased with increasing SOR007 dose; however, the increases in mean C max and AUC 0-
[ADDRESS_808586] dose, 49.9 mg/kg/day, with an associated combined- sex C max of 12.5 ng/mL and an 
AUC ( 0-24) of 149 ng•hr/mL. Significant paclitaxel accumulation was noted following 
repeated -once daily topi[INVESTIGATOR_609904] 28 days. 
• A single -dose, GLP  intraperitoneal (IP) toxicity study in the rat, conducted under IND 
073529, compared nanoparticulate paclitaxel dosed to the maximum tolerated dose (MTD) versus Taxol® dosed to the MTD. Results of this study indicated that the toxicity 
associated with IP administration of nanoparticulate paclitaxel is less than that associated 
with IP Taxol administration.  
• Subcutaneous administration of a single dose (20 mg/kg ) of nanoparticulate paclitaxel in 
a non- GLP study in male rats resulted in no evidence of ulcerat ion, irritation or other 
drug- related toxicity.  
Clinical Summary  
SOR007 has not been administered to humans for topi[INVESTIGATOR_609900].  A 
Phase 1 clinical trial of SOR007 for the indication of moderate to severe plaque psoriasis was 
comp leted under IND 126915 (Protocol SOR007- 2016- 01). Thirteen subjects with chronic plaque 
type psoriasis received occlusive application of six topi[INVESTIGATOR_29899]:  SOR007 at 0.15%, 0.3%, 
1.0%, and 2.0%, vehicle, and an active comparator approximately daily  for up to 10 treatments 
over a 12- day period.  Approximately 200 µL of each formulation was be applied on each dosing 
day. The total body surface area exposed to SOR007 was 4.52 cm2, or 0.03% total body surface 
area of a 1.[ADDRESS_808587]. Calculated on a mg/kg or 
mg/m2 basis, the paclitaxel applied topi[INVESTIGATOR_609905] 12- day study would be approximately 0.1 
mg/kg (3.8 mg/m2) per d ay, or 1.0 mg/kg (38 mg/m2) total exposure for a 60- kg subject. The 
primary endpoint was the change from baseline in psoriatic skin thickness (assessed by 
[CONTACT_609926] (ELB) of the psoriatic infiltrate using 22 
MHz so nography). Clinical assessment, photo documentation, and PK analysis were also 
performed.  No treatment related AEs were reported by [CONTACT_609927] 10 daily topi[INVESTIGATOR_609906]007. There were no reports of local skin reactions seen under the hydrocolloid 
dressing during the 12- day study period.  
Twelve subjects completed the trial and were available for PK analysis. Blood was drawn on Day 
11 prior to dosing and then again at 1, 4, 8 and 24 hours after dosing. Following topi[INVESTIGATOR_609907] 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808588], Inc.  CONFIDENTIAL  Page 15 of 62 of ~5.7 mg daily dose (57 mg cumulative dose) of SOR007, Day 11 plasma paclitaxel 
concentrations over the 24- hr sampling interval were below the limit of quantitation (LLOQ of 10 
pg/mL) for [ADDRESS_808589], and this level (17.7 pg/mL) was near the lower limit of quantitation.  Thus, paclitaxel systemic exposure was negligible in psoriatic patients concomitantly receiving 200 µL each of the 0.15, 0.3, 1, and 2% SOR007 ointment formulations. 
1.2 Rationale  
Cutaneous metastases occur in up to 10% of cancer patients (excluding melanoma) ( Spratt 2014; 
Alcaraz 2014 ). Cutaneous metastases can cause considerable morbidity, leading to infection, 
bleeding, disfigurement and pain. The negative impacts to quality of life (QOL) for this population 
with advanced disease can be devastating ( Spratt 2014).  
Despi[INVESTIGATOR_609908], a standard of care remains elusive. Treatment is complicated by [CONTACT_609928], poor patient performance, previous radiation 
therapy and short duration of overall survival. These factors make surgery and radiation unfeasible in most patients ( Sideras 2008; Campana 2016; Cabula 2015). Systemic chemotherapy has 
negligible impact on most cutaneous metastases ( Fernandez -Anton Martinez 2013; Spratt 2014). 
Additional therapi[INVESTIGATOR_609909] (ECT), photodynamic therapy (PDT), intralesional therapy (ILT), and topi[INVESTIGATOR_8588] (TT). In a meta- analysis of 47 
prospective studies of 4,313 cutaneous metastases, the objective response rate to the therapi[INVESTIGATOR_014]  
(including radiotherapy) was 60.2% ( Spratt 2014). ECT demonstrated the best response rate 
(complete response rate 47.5%); however, ECT is an inpa tient procedure requiring general 
anesthesia and often results in notable pain and dermatologic toxicity (inflammation, 
hyperpi[INVESTIGATOR_371], and ulceration) ( Cabula 2015). The less invasive alternatives, such as 
intralesional therapy and topi[INVESTIGATOR_609910]. 
When effective reduction of cutaneous metastases cannot be achieved, as is often the case, 
healthcare providers must fall back on palliative wound care remedies ( Fernandez -Anton Martinez 
2013). There is theref ore a significant unmet need for an effective, less invasive alternative therapy 
for cutaneous metastases in patients already struggling with significant morbidity from the symptoms of and treatments for advanced primary cancer.  
Paclitaxel, formulated as T axol or Abraxane, is approved by [CONTACT_609929], including ovarian cancer, breast cancer, non -small cell lung cancer, and 
pancreatic cancer ( Taxol Package Insert, Abraxane Package Insert ). Paclitaxel has also been used 
off-label with some effect in numerous other cancers, including bladder cancer, cervical cancer, 
endometrial cancer, esophageal cancer, squamous cell carcinoma of the head and neck, prostate 
cancer, gastric cancer, and testicular cancer, among others ( DeVita 2001). This, in conjunction  
with paclitaxel’s cytotoxic mechanism of action, provides the basis for the investigation of 
nanoparticulate paclitaxel (formulated as SOR007) for the topi[INVESTIGATOR_609900]. Based on nonclinical studi es of SOR007, it is believed that the nanoparticles will 
achieve a depot effect, providing a continuous dose of paclitaxel to the diseased skin over time 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808590], Inc.  CONFIDENTIAL  Page 16 of 62 with limited systemic exposure. It is also anticipated that topi[INVESTIGATOR_609911]007 will be well tolerated, allowing for repeat administration if necessary.  
1.3 Potential Risks and Benefits  
1.3.1 Known  Potential Risks  
There are currently no known risks  associated wi th SOR007 applied topi[INVESTIGATOR_609912].  
Intravenous a dministration of pa clitaxel  can lead to AE . Systemic exposure to paclitaxel by 
[CONTACT_17838], ingestion or inhalation was associated with following AE : 
• Bone marrow suppression;  
• Hypersensitivity reaction; 
• Hypotension;  
• Peripheral neuropathy;  
• Myalgia/Arthralgia;  
• Infection;  
• Mucositis;  
• Nausea/Vomiting;  
• Diarrhea;  
• Neurotoxicity;  
• Alopecia;  
• Renal impairment; 
• Hepatic impairment;  
• Hypospermatogenesis;  
• Injection site reaction.  
Most AE associated with paclitaxel are temporary and will resolve in time. However, time to 
resolu tion of specific AE  is unknown and can vary widely depending on concomitant medications, 
therapi[INVESTIGATOR_014], and medical condition.  
Nonclinical studies have shown that paclitaxel  can cause fetal harm when administered during 
pregnancy . There are no adequate and well -controlled clinical studies in pregnant women. If 
paclitaxel  is used during pregnancy, or if a  patient becomes pregnant while receiving paclitaxel , 
the patient should be apprised of the potential hazard to the fetus.  
1.3.2 Known  Potential Benefits  
There are currently no known benefit s for SOR007 applied topi[INVESTIGATOR_547943] c utaneous m etastases.  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808591], Inc.  CONFIDENTIAL  Page 17 of 62 2 OBJECTIVES AND PURPOSE  
The primary objective of this study is to evaluate the safety and tolerability of topi[INVESTIGATOR_609897]007 
ointment applied to cutaneous metastatic lesions. The s econdary objective s are to obtain 
preliminary information on the efficacy of topi[INVESTIGATOR_609897]007 ointment applied to the cutaneous 
metastatic lesions, reduction in pain and to describe the  pharmacokinetics of topi[INVESTIGATOR_609897]007 
Ointment. 
3 STUDY DESIGN AND ENDPOINTS  
3.1 Description of the Study Design  
This is a P hase 1/2, open- label, dose-rising  study evaluating the safety , tolerability,  and 
preliminary efficacy of three concentrations of SOR007 ( 0.15%, 1.0%, and 2.0%) applied topi[INVESTIGATOR_609913]- melanoma  cutaneous metastases.  
Subjects will be screened and eligibility confirmed up to 14 days prior to treatment with SOR007.  
Safety Reviews  
Regular s afety reviews will be conducted by [CONTACT_137984] r on an ongoing monthly basis 
throughout the dose escalation and dose expansion portions of the study. Safety data to be reviewed 
will include, but will not be limited to , medical history, physical examinations, disease status, vital 
signs, concomitant medications, adverse events, and laboratory results. The CTCAE ( version 4.0) 
criteria will be used to classify the severity of adverse events and determine dose limiting toxicity.  
The study will include a dose escalation phase and a dose expansion phase .  
Dose Escalation Phase:  
During the dose  escalation phase, the study will follow a standard 3+[ADDRESS_808592] cohort commencing treatment on Day 1 with 0.15% SOR007 ( see Figure 1 ). Dose 
escalation of SOR007 will be determined by [CONTACT_28749] ( SMC ) per the 
charter, which will be in place prior to the first subject entering the study. The SMC will review all available data after the last subject in each cohort of three subjects completes 15 days of 
treatment to determine whether dose escalation may continue .  
If a single dose limiting t oxicity (DLT) is identified in one of three  subjects in the cohort, a 
further three  subjects wil l be enrolled at the same dose level. If one or more  DLT occur  in the 
three additional  subjects enrolled in the cohort, dose escalation will stop and the prior dose level 
will be regarded as the Maximum Tolerated Dose (MTD) and taken forward into the dose expansion phase. If no further DLT are identified, dose escalation will continue, until either a DLT is identified at a higher dose or the top dose of 2% is reached.
  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808593], Inc.  CONFIDENTIAL  Page 18 of 62 Dose Expansion Phase:  
In the dose  expansion phase , additional subjects will be enrolled to reach a maximum of 16 subjects 
at the dose level determined to be the MTD  (or the top dose, 2.0% SOR007) in the dose escalation 
phase . The option of [ADDRESS_808594] disease progression,  additional systemic chemotherapy or other metastatic treatment 
requirements.  
3.2 Primary Endpoint  
Safety and tolerability, as demonstrated by [CONTACT_20721], changes in laboratory assessments, 
physical examination findings, and vital signs.  
3.3 Secondary Endpoints  
• For the purposes of the following secondary endpoint s for efficacy , eligible lesion  
measurements  and analysis of photographs  will be conducted by [CONTACT_609930] . 
Eligible lesion identification will be performed  by [CONTACT_941] I nvestigator at the clinical site at 
screening and confirmed at baseline for eligibility determination only, b y the RECIST 
(version 1.1) definition of measurable tumors (≥ 10mm in its longest diameter) (Eisenhauer 
2009).  
o Objective tumor response, defined as the differenc e in the sum of eligible tumor 
diameter (s) within the treatment area  between baseline and Day 43 or 70 (i.e. [ADDRESS_808595] dose in the dose escalation and expansion phases depending on dose regimen ). Tumor surface area and response will be assessed at all visits.  
Change in surface area will be assessed using a calibrated gri d measurement system 
(ImageJ freeware ) provided by [CONTACT_18121]. Photographs will be uploaded to a  secure 
Citrix ShareFile or site restricted -access file, by a designated site staff member  
within 2 days of each visit. The Sponsor will measure and analyze the lesions using 
ImageJ as they are received.  
o Objective Clinical Response is defined  as subjects with Complete Clinical 
Response (CR) + Partial Response (PR) , further defined as the percentage of 
patients who achieve complete clinical response or partial response [ADDRESS_808596] 
diameter (s) of eligible target lesion (s) within the treatment area [ADDRESS_808597] response recorded from the start of study treatment until the end of the study ( i.e. 28 Treatment days at Visit 6/Day 43 or 56 
Treatment days at Visit 7, Day 70) .  
o Complete clinical response (CR) is defined as absence of any detectable residual 
disease in eligible lesion (s) within the treatment area ; partial response (PR) as at 
least a 30 % decrease in the sum of the diameters of the eligible lesion (s) within the 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808598], Inc.  CONFIDENTIAL  Page 19 of 62 treatment area compared to baseline (Visit 2) ; and progressive disease (PD) as at 
least a 20% increase in the sum of diameters of eligible lesion (s) within the 
treatment area, taking as reference the smallest sum on study. In addition, the sum 
must also demonstrate an abs olute increase of at least 5 mm . Stable disease (SD) is 
defined as the sum of eligible lesion diameter (s) between that defined as PR or PD.  
o The appearance of new non-target lesions during participation in this study does 
NOT constitute progressive disease.  
• Pain at the treatment area will be measured by [CONTACT_250115] (NRS -11). Change 
in pain will be analyzed from baseline to Day 43 or 70. 
• To describe the pharmacokinetics of topi[INVESTIGATOR_609897]007 Ointment applied to metastatic  
lesions . 
3.4 Exploratory Endpoints  
Appearance of new lesions within the treatment area.  
4 STUDY ENROLLMENT AND WITH DRAWAL  
4.1 Participant  Inclusion Criteria  
1. Signed informed consent;  
2. Male and f emale p atients  ≥ 18 years of age; 
3. Malignancies resulting in  cutaneous metastasis originating  from : breast, lung, head and 
neck, pancreatic, urinary bladder, prostate, testicular, ovarian, uterine, cervical, gastric, 
adrenal, t hyroid, p arathyroid  cancers , or other solid tumors ; 
4. Cutaneous metastases  diagnosis confirmed prior to consent  by [CONTACT_609931] , but is not limited to : biopsy ; conventional radiography ; 
imaging techniques to include bone scan (scintigraphy), computed tomography (CT), 
fluorodeoxyglucose -positron emission tomography (FDG -PET)/CT) , magnetic resonance 
imaging (MRI), F -fluoromisonidazole -(F-FMISO) PET/CT, fluorothymidine -(FLT) 
PET/CT, fluoroestradiol -(FES) PET/CT, and PET/MRI ; 
5. ECOG Grade 0 – 2, with minimum life e xpectancy of at least 3 months;  
6. At least one  baseline eligible lesion. Per RECIST criteria (version 1.1) , an eligible  lesion 
at baseline is considered measurable when ≥  10mm diameter in the longest diameter ; 
7. Willing to refrain from using lotions, creams , etc. during the treatment period to the 
treatment area;  
8. Subjects with adequate organ and bone marrow function as defined below:  
o ANC ≥ 1,500/µl  
o Hemoglobin ≥ 9.5 grams/dL  
o Platelets ≥ 75,000/µl  
o  AST ( aspartate transaminase or SGOT )/ALT ( alanine aminotransferase or SGPT ) 
≤ 3.[ADDRESS_808599] and total bilirubin ≤  2.[ADDRESS_808600] with no evidence of cholestasis  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808601], Inc.  CONFIDENTIAL  Page 20 of 62 o Creatinine ≤ 1.5x ULN ; 
9. Last dose of any s ystemic non-taxane cytotoxic chemotherapy completed at least  one day 
prior to Day 1. L ast dose of any s ystemic taxane cytotoxic chemotherapy completed at least   
4 weeks prior to Day 1;  
10. Willing to use appropriate  birth control for patients of child- bearing potential ; 
11. Abstinence from all manner of physical contact [CONTACT_609932] 2 
weeks after the treatment phase.  
4.2 Participant Exclusion Criteria  
1. Open  or ulcerated wound (s) extend ing through the dermis within  the treatment area;  
2. Colorectal, hepatocellular, gallbladder, cholangiocarcinoma, neuroendocrine, melanoma s, 
hematological and central nervous system ( CNS ) malignancies ; 
3. Active viral hepatitis A, B, or C or preexisting or acute liver disease;  
4. Systemic treatment or localized treatment  to target  area with the following within the [ADDRESS_808602] treatment visit: radiotherapy, intralesional therapy; laser therapy 
surgery (other than biopsy ) local hyperthermia, levuli nic acid, 5 -fluorouracil, high potency 
corticosteroids (including systemic steroids), retinoids, diclofenac, hyaluronic acid, imiquimod;  
5. Electiv e surgery for treatment of the cutaneous metastases during the study and up to [ADDRESS_808603] treatment  to achieve study objectives;  
6. Known allergic reactions, irritations or sensitivity to the active ingredients or other components of SOR007;  
7. Symptoms of a clinically significant illness that may place the subject at risk by [CONTACT_609933] e four weeks before first treatment 
and during the trial;  
8. Participation in the treatment phase of another clinical trial within the four weeks prior to 
treatment in this clinical trial; 
9. Investigator’s opi[INVESTIGATOR_411202]’s  probable noncompliance or inabilit y to understand the 
trial and /or give adequate informed consent;  
10. Evidence  of current chronic alcohol or drug abuse ; 
11. Pregnancy and/or lactating.  
4.3 Strategies for Recruitment and Retention  
Sufficient subjects will be screened to allow for a minimum of three subjects  up to a maximum of 
28 subjects  to be enrolled in the trial. It is not anticipated that any advertising will be required for 
recruiting to the study. Subjects will be recruited and screened for eligibility and will proceed to 
treatment in cohorts  of three. A low ECOG grade is required to  maximize the probability that 
subjects will participate for the full duration of the study.  
Total study duration is estimated at about 15 months. 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808604]. Any reason 
for withdraw al and/or early termination will be documented in the source notes and in the 
Electronic Data Capture system (EDC).  
Other than t he potential for local toxicity reactions, there is no reason currently anticipated that 
would cause the Investigator to terminate a subject’s participation in the study once treatment has 
been initiated . It is very important that any events occurring be c aptured and followed for the safety 
of the subject.  
Subjects may be non -compliant with the study protocol in a way that much of the data is not 
captured which would usually require withdrawal for non- compliance. For the purposes of this 
study, subjects should not be withdrawn in this situation.  
Clinical AE, laboratory abnormalities, or other medical conditions/situations may occur which 
would usually re quire cessation of  study  treatment. In these instances,  it is very important that all 
of these events be captured, followed, and documented, and therefore a subject sh ould not be 
withdrawn but rather  followed up to  study completion . 
Should the Investigator feel it to be in the best interest of the subject to be  withdrawn from the 
study, the Investigator will immediately contact [CONTACT_609934].  
4.4.[ADDRESS_808605] is withdrawn they would undergo final study visit evaluations ( Visit 6 End -
of-Study evaluations) which include but are not limited to  vital signs, AE collection and 
concomitant medication updates.   Subjects that refuse or fail to appear for clinic visits following SOR007 treatment and fail to 
respond to or cooperate with reasonable and diligent attempts at contact [CONTACT_609935] -to-follow -up. Reasonable and diligent contact [CONTACT_609936]. E mails and registered 
mail correspondence should be filed  in the subject’s medical record  to document due diligence.  
If a subject repeatedly misses study visits or remains non- compliant following SOR007 treatment , 
and where the majority of data is not avail able, the option to replace that subject in the cohort 
exists, however the data that is collected from the non -compliant subject may still be used in the 
evaluations in this study.  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808606], Inc.  CONFIDENTIAL  Page 22 of 62 4.5 Premature Termination or Suspension of Study  
This study may be temporarily suspended or prematurely terminate d by [CONTACT_609937].  Written notification, documenting the reason for the study suspension 
or termination, will be provided by [CONTACT_609938]. If the study is 
prematurely terminated or suspended, the PI [INVESTIGATOR_609914]. 
Circumstances that may warrant termination include, but are not limited to: 
• Determination of unexpected, signific ant, or unacceptable risk to participants;  
• Insufficient compliance with protocol requirements;  
• Data that are not sufficiently complete and/or evaluable;  
• Determination of futility  
o During the dose escalation phase,  the majority of the lesions in  the 50 cm
2 
treatment area of study subjects  who receive the maximum tolerated dose of 
SOR007 are found to increase in size at the end of the 28 or 56 day s of treatment 
period. If the study is considered futile, it will be terminated and the dose 
expansion phase will  not proceed.  
Study may resume once concerns about safety, protocol compliance, and data quality are addressed 
and satisfy the sponsor, IRB, and/or FDA.  
5 STUDY DRUG  
5.1 Study Drug (s) Description  
5.1.1 Acquisition  
The drug substance, paclitaxel, USP, is supplied by [CONTACT_609939], LLC, Delta, BC, Canada . 
Bulk paclitaxel is converted to nanoparticles using a PCA technique, which employs supercritical 
carbon dioxide and acetone to generate paclitaxel nanoparticles within a well - characterized 
particle size distribution . The study drug , SOR007, will be manufactured by [CONTACT_609940]  (DDL)  and provided for use in this study as an ointment.  
The study drug  will not be shipped to the study site until all Regulatory Documentation has been 
provided by [CONTACT_779] a nd the site is ready for study Initiation, at which time the study drug will be 
released for shipment. Shipment will be via courier, temperature controlled 68˚ to 77˚F (20˚ to 
25˚C ) and  will occur prior to and in conjunction with the Site Initiation visit.  Study drug will be 
shipped to the site  Pharmacy where it will be stored according to the conditions required (see 
5.1.3).  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808607], Inc.  CONFIDENTIAL  Page 23 of 62 5.1.2 Formulation, A ppearance, Packaging, and Labeling 
The study drug , SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment, is formulated with 
nanoparticulate paclitaxel at levels ranging from 0.15% to 2% suspended in an a sealed 15g 
laminate tube  and will be labeled to include the following:  
Subject #: __________________ Date Opened ______ / ______ / ______ 
Study Number: SOR007 -  __________________________________ 
Product Name: [CONTACT_609970]007 (Uncoated Nanoparticle Paclitaxel) Ointment X %, 15 g   
Store at 20- 25°C (68 -77°F)  
Keep out of the reach of children.  
Caution: New Drug – Limited by [CONTACT_4496] (or [LOCATION_002]) Law to investigational use.  
DFB Soria , LLC, US Biotest, [ADDRESS_808608] Storage and Stability  
Stability studies show that SOR007 ointment is stable when stored at controlled room temperature 
(25 °C/60% relative humidity) for up to 6 months and accelerated conditions (40 °C/75% relative 
humidity) for up to 6 months. 
Prior to administration at the hospi[INVESTIGATOR_307]/clinic, the SOR007 ointment tubes will be stored at the 
Pharmacy, temperature controlled at 20˚ to 25˚C (68˚ to 77˚F); excursions permitted between 15 -
30°C (59- 86°F).  
5.1.[ADDRESS_808609] in small tubes.  
5.1.5 Dosing and Administration  
Application of SOR007 will occur twice daily, at approximately the same time s each day  (morning 
and evening) , for 28  or 56 days. Using a gloved hand, subjects will self-apply one Finger Tip Unit 
(FTU) of SOR007 to the  entire 50 cm2 treatment area previously outlined by [CONTACT_609941] . Note: There may be multiple  lesions in the 50 cm2 marker -outlined 
area.  
A FTU is defined as the amount of ointment expressed from a tube with a 5 mm diameter nozzle, 
applied from the distal skin -crease to the tip of the index finger of an adult. The "distal skin- crease" 
is the skin crease over the joi nt nearest the end of the finger.  One FTU will cover approximately 
50cm2, the entire  treatment area .  One FTU = 0.5 g, which will amount to  approximately  1 g/day 
or 7 g/week of ointment .  
Prior to administration of SOR007, the treatment area should be gently cleansed. Apart from drug 
application  and area cleansing , all physical touching of the treatment area , including application 
of oils, creams and harsh soaps, is to be strictly avoided. Subjects will be provided with an 
instruction card as a guide for application and will receive  application training by [CONTACT_609942] 2, 3 , 4 and 5, as needed.  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808610], Inc.  CONFIDENTIAL  Page 24 of 62 5.1.6 Route of Administration  
Topi[INVESTIGATOR_2855].  
5.1.7 Dosing and Dose Escalation  
This study will be conducted in two phases : a dose escalation phase structured with a standard 3+3 
dose-ascending design (Figure 1) and a dose expansion phase enrolling sufficient subjects to reach 
a maximum of 16 total subjects total at the maximum tolerated dose (MTD ) or highest  dose of 
SOR 007 (0.15%, 1.0% or 2.0%) as determined in the dose escalation phase  (see Section 7.6).   
Safety reviews for decisions on dose  escalation will be conducted after the last subject in each 
cohort of three subjects completes 1 5 days of treatment . Guidance on the criteria to be used in the 
determination of the benefit /risk balance for dose escalation  can be found in Section 7.5 Study 
Halting Rules . 
5.1.8 Dose Adjustments/Modifications/Delays  
None.   
5.1.[ADDRESS_808611] to cease treatment with SOR007.  
28 Treatment Days  
If treatment with SOR007 ceases at any point prior to Day 28 treatment subjects should complete 
Visit 6 -  End of Study procedures and the Visit 7 safety assessment study evaluations ( See 6.5.4).  
56 Treatment Days  
If treatment with SOR007 ceases at any point prior to Day 56 treatment subjects should complete 
Visit 7 -  End of Study procedures and the Visit 8 safety assessment study evaluations ( See 6.5.4).  
Due to the nature of both the disease and of paclitaxel, it is possible that the epi[INVESTIGATOR_018]/dermal covering over the treated target cutaneous metas tatic lesion will break down after initiation of 
treatment with SOR007. SOR007 may, in this scenario, continue to be applied to the treatment 
area. If new ulceration occurs,  this is considered a DLT . Following review of the study data, the 
Medical Monitor will provide written documentation confirming all treatment cessations for each 
applicable subject .   
5.1.[ADDRESS_808612]  to obtain 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808613] . This step (weighing of  tubes) may also be conducted 
by [CONTACT_609943] . Scales and calibration weights may be provided to 
sites where there is no access to a ‘ weighing scale ’. The subject s will be trained to self -dose 
(application) by [CONTACT_597890]. The subject s will apply the first dose to the ‘marker -
outlined area’ under study staff supervision. Subjects will be instructed on how to care for the 
treatment area (cleansing), what to avoid ( creams , lotions, harsh soaps), SOR007 storage and 
requirements to bring SOR007 ointment tubes to each subsequent visit ( Visits 3, 4, 5 or  6, if 
applicable) , at which point  all returned tubes will be visually inspected and weighed in the 
pharmacy. The subject s will be provided new SOR007 ointment tube (s) at Visits  2, 3, 4 or  5, if 
applicable. Subjects may use any SOR007 ointment tube (s) until it is empty, before starting a 
new SOR007 ointment tube . Subjects will also be provided a n instruction card at the study start 
and a diary at each clinic visit as a dosing reminder and to document all SOR007 self -dosing 
details , adverse events and concomitant medications taken . For subjects that have difficulty 
applying the study drug or requiring assistance, a care- giver or spouse may be trained in study 
drug application, if allowed by [CONTACT_236863]/or IRB.  
5.2 Study Drug  Accountability Procedures  
The Investigator  or designee  will maintain adequate records showing the receipt, dispensing, 
return, or other disposition of the study  drug, including the date, quantity, batch or code number  
(if applicable) , and identification of subjects (number, i nitials  (as allowed by [CONTACT_609944] )) who received study medication. 
Accountability will be conducted on the individual  tubes . 
Used tubes will be retained in the Pharmacy for accountability purposes and will not be disposed 
of until s ponsor accountability  monitoring is completed. Used tubes will be retained in the clinic 
until the site receives sponsor directives for used/unused study drug tube return to the sponsor or 
delegate.  
Under no circumstances will the Investigator supply clini cal material to other Investigators or 
clinicians or allow the supplies to be used other than as directed by [CONTACT_609945].  
6 STUDY PROCEDURES AND SCHEDULE  
6.1 Study Procedures/Evaluations  
6.1.1 Study Specific P rocedures  
The following procedures and evaluations will be performed as part of this study : 
• Review and documentation of demographics, significant past and current medical history , 
including allergies ; 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808614], Inc.  CONFIDENTIAL  Page 26 of 62 • Review and documentation of concomitant prescription and non- prescription medications;  
• Review and documentation of diagnosis of cutaneous metastases  of non- melanoma origin  
and previous treatments including surgical and chemotherapeutic records;  
• A pregnancy test at screening  for female subjects ; 
• A comprehensive physical examination  at screening only; at all subsequent visits, the 
investigator will perform a physical examination  only if deemed necessary, otherwise no 
physical examination needed per protocol ; 
• Vital signs ( blood pressure, heart rate, re spi[INVESTIGATOR_1487], temperature ); 
• Body weight and height  (at screening only) ; 
• Pain at the treatment area will be assessed with the Numeric Rating S cale ( NRS -11) at 
screening  Visit 1 and at each study visit. 
• Measurement of lesions with calipers ;  
• Photography of the treatment area (Section 6.3)  
• SOR007 to be applied topi[INVESTIGATOR_609915] 28 or 
56 days ; 
• Blood samples for routine hematology and serum chemistry at every visit;  
• PK blood collection at  [ADDRESS_808615] application  (Day 1/Visit 2 plus 24 hours) , 
and Visits 3, 4, 5 and 6 and 7, if applicable .  
• Urine dipstick at screening and last subjec t visit; and  
• Subject diary  to be completed daily . 
• Every effort should be made to schedule the subject clinic visits early in the morning to 
ensure the ‘morning’ and ‘evening’ application routines are adhered to and conducted at approximately the same time every day .   
6.1.[ADDRESS_808616] of care treatment at the Investigator’s institution is not part of this study. Medical care 
during this study is at the discretion of the Investigator.  At the time of the first study drug dose, 
the subject should not be scheduled  for systemic chemotherapy. If, after the first study drug dose 
application, due to progression of disease or at the Investigator ’s discretion , the need arises  for 
chemotherapeutic intervention , such treatment  will be initiated  at any time during the conduct of 
the stud y (See 6.6) . All treatments and medications must be recorded in the subject’s record. 
Surgical excision may only be scheduled at least [ADDRESS_808617]’s best 
interest to receive surgical excision or other prohibited treatment sooner than four weeks after last 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808618] will be permitted to receive such treatment in accordance with 
Section 6.6.2. 
6.2 Treatment Area Selection  
At baseline (Visit 2), the Investigator will identify a treatment area of [ADDRESS_808619] criteria (version 1.1), an eligible lesion is considered measurable 
when ≥  10mm diameter in the longest diameter.  
The Investigator will outline the treatment area in permanent marker . All lesions within the 
treatment area will be measured by [CONTACT_609946] . There may be multiple lesions present, in addition to the target lesion , in the 50 cm2 
outlined area. All lesions in the treatment area will be measured and tracked as described in this 
protocol  (Section 3.3) . 
6.[ADDRESS_808620] focal length digital camera of the treatment areas 
will be performed at baseline (Day 1/ Visit 2)  and at each subsequent study  visit (Days 8, 15, 29, 
and  57, and 70, if applicable ) or early withdrawal from the study, as applicable. The photographs 
will be taken under standardized conditions. Cameras and associated equipment will be provided 
to all Investigators , if needed. At least two  global photos  will be taken to reference the treatment 
area’s location on the subject’s body  and at least two close- up photos  of the treatment area will be 
taken. In every  close- up photo, the required photographic documentation of the treatment area will 
include a centimeter ruler to reference scale and a label with  the subject number , calendar date and 
study visit number. No non- study specific information will be included in the label. S tudy staff 
will be instructed to upload the s ubject photographs to a secure, password protected Citrix 
ShareF ile or site restricted -access file, that will be accessible only by [CONTACT_779], the Medical Monitor , 
and the Sponsor . The Sponsor will analyze the images and measure the lesions using  the Image J 
JAVA image processing program as photographs are uploaded by [CONTACT_737].  
6.4 Laboratory Procedures/Evaluations  
6.4.1 Clinical Laboratory Evaluations  
Clinical laboratory assessments will be conducted at the local CLIA certified laboratory routinely 
used by [CONTACT_737].  
The following laboratory tests will be performed at the Screening visit and Visits 2- 6, and 7, if 
applicable:  
• Routine complete total blood count including red blood cells (RBC), white blood cells 
(WBC), hemoglobin, hematocrit, platelets, mean corpuscular hemoglobin (MCH), mean 
corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), and 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808621], Inc.  CONFIDENTIAL  Page 28 of 62 complete differential to include absolute and relativ e counts for all hematological 
paramete rs measured;  
• Serum Chemistry, including albumin, total bilirubin, liver function tests (AST, ALT, GGT, 
ALP), blood urea nitrogen (BUN), creatinine, sodium, potassium, calcium, chloride, 
magnesium, and total protein;  
• Urinalysis (dipstick) , including  specific gravity, pH, RBC, WBC, protein, and glucose  will 
be performed at screening and V isit [ADDRESS_808622].   
6.4.2 Other Assays or Procedures   
Blood samples will be collected to analyze pharmacokinetic (PK) activity for all  subjects . Samples 
will be collected at [ADDRESS_808623]  application (Day 1/Visit 2  plus 24 hours), Visits 3, 4 
and 5 ( prior to the first daily application ); Visits  6 and 7 ( at any time during the visit) .  
6.5 Study S chedule 
6.5.1 Screening  
Visit 1 (Days - 13 to Day 0)  
The following screening procedures and assessments must be completed, documented and 
reviewed by [CONTACT_737], within [ADDRESS_808624] of care lab oratory and clinical assessments will be allowed if 
obtained prior to consent only if performed within the screening timeperiod or 14 days prior to 
Day 1 : 
• Written informed consent including comprehensive discussion of the study schedule, procedures and subject protocol require ments;  
• Review of previous medical records, demographics, allergies, s ignificant past medical 
history ; 
• Review and documentation of concomitant prescription and non- prescription medications;  
• Review and documentation of diagnosis of cutaneous metastases  of non- melanoma origin 
and previous treatments including surgical and chemotherapeutic records;  
• A comprehensive physical examination ;  
• Vital signs ( blood pressure, heart rate, respi[INVESTIGATOR_1487] ), temperature, body weight and 
height;  
• ECOG performance status;  
• Pain assess ment  of the treatment area wit h the Numeric Rating S cale ( NRS -11); 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808625], Inc.  CONFIDENTIAL  Page 29 of 62 • Lesions will be measured  with calipers . The target  lesion will be determined at baseline by 
[CONTACT_39694] (version 1.1) definition of measurable tumors ( ≥ 10mm in its longest 
diameter ); 
• Blood samples for routine hematology and serum chemistry, as per Section 6.4.1;   
• Urinalysis by [CONTACT_5230];  
• Pregnancy test  for female subjects ; 
• Review of inclusion and exclusion criteria  and determination of eligibility . 
6.5.2 Enrollment/Baseline  
Visit 2 ( Day 1)  
The following procedures and assessments must be completed, documented and reviewed by [CONTACT_609947][INVESTIGATOR_609897]007 ointment a pplication : 
• Medical history updates to include any events occurring since Visit 1, up to the first study 
treatment application ; 
• Review and documentation of current concomitant prescription and non- prescription 
medications; 
• A problem -oriented physical examination , only  if determined necessary by [CONTACT_10670] ; 
• Vital signs measurement ( blood pressure, heart rate, respi[INVESTIGATOR_1487], temperature ); 
• Lesions will be measured  with calipers . The target  lesion will be confirmed  at baseline by 
[CONTACT_39694] (version 1.1) definition of measurable tumors ( ≥ 10mm in its longest 
diameter ). All other lesion (s) in the treatment area will also be measured.  
• Routine hematology , serum chem istry and urinalysis . 
• Review of inclusion and exclusion criteria and determination of eligibility up to just prior 
to the first study treatment application, to confirm proceed ing to treatment. After these 
assessments have been completed, the subject will receive topi[INVESTIGATOR_609916]007.  
• Pain assessment of the treatment area wit h the Numeric Rating Scale (NRS -11) to be 
assessed prior to treatment area cleansing or drug application;  
• The [ADDRESS_808626] one eligible lesion will be selected by [CONTACT_3786], washed with warm soapy water and outlined with a permanent marker;  
• Each lesion within the treatment area will be documented in the source and tracked for the duration of the study for changes in size and app earance;  
• Photography of the treatment  area and eligible lesion(s), incorporating a ruler for size 
evaluation;  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808627], Inc.  CONFIDENTIAL  Page 30 of 62 • For this first application , the Investigator will demonstrate proper application technique as 
described in Section 5.1.5.  
The s ubject will be supplied with the appropriate number of tubes of SOR007 for treatment 
application  (until Visit 3)  and a subject diary for daily completion. The subject will be instructed 
to self -apply SOR007 twice daily and to bring with them the SOR007 oin tment tube to  Visit 3 
(Day 8).  
 
PK Collection 24 Hours  (+/- 2 hrs)  
The subject will return to the clinic for PK  sample collect ion at 24 hours (+/- 2 hours)  after the 
Visit 2/Day [ADDRESS_808628] SOR007 ointment a pplication. 
6.5.3 Treatment   
Visit 3 (Day 8 ± 1 Day)  
• Subject will retu rn used SOR007 ointment tube for dosing compliance (Section 5.1.10) 
and study drug accountability (Section 5.2) purposes;  
• Review and documentation of concomitant prescription and non- prescription 
medications; 
• A problem -oriented physical ex amination only  if determined necessary by [CONTACT_10670] ; 
• Vital signs (blood pressure, heart rate, respi[INVESTIGATOR_609917]) ;  
• Pain assess ment  of the treatment area wit h the Numeric Rating S cale ( NRS -11) prior to 
treatment area cleansing or drug application;  
• Photography of the treatment area and eligible  lesion s, incorporating a ruler for size 
evaluation;  
• Blood sample  collection  for routine he matology and serum chemistry, as per Section 6.4.1;  
• Day [ADDRESS_808629] ion prior to study drug application;  
• Application of SOR007;  
• Adverse events  review ; 
• Subject will be supplied with the appropriate number of tubes of SOR007 for treatment 
application  until  the next visit;  
• Subject diary  from Visit [ADDRESS_808630] source documents  by a delegated staff; and  
• A new diary  to be provided to the subject for daily completion. 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808631], Inc.  CONFIDENTIAL  Page 31 of 62 Visit 4 (Day 15 ± 1 Day)  
• Subject will return SOR007 ointment tube for dosing compliance ( Section 5.1.10) and 
study drug accountability ( Section 5.2) purposes;  
• Review  and documentation of concomitant prescription and non- prescription medications;  
• A problem -oriented physical examination only  if determined necessary by [CONTACT_10670] ; 
• Vital signs ( blood pressure, heart rate, respi[INVESTIGATOR_1487], temperature );  
• Pain assess ment  of the treatment area wit h the Numeric Rating S cale ( NRS -11) prior to 
treatment area cleansing or drug application;  
• Photography of the treatment area and eligible lesion s, incorporating a ruler for size 
evaluation;  
• Blood sample collection  for routine hematology and serum chemistry, as per Section 6.4.1;  
• Day [ADDRESS_808632] ion prior to study drug application;  
• Application of SOR007;  
• Adverse events  review ; 
• Subject will be supplied with the appropriate number of tubes of SOR007 for treatment  
until the next visit;  
• Subject diary from Visit [ADDRESS_808633] source documents by a delegated staf f; and  
• A new Visit [ADDRESS_808634] for daily completion. 
Visit 5 (Day 29 + 2 Days)  
• Subject will self -apply the last dose of SOR007 the evening prior to the visit;  
• Day 29 PK sample collection at any time during  the visit;   
• Blood samples will be collected for routine hematology and serum chemistry, as per 
Sectio n 6.4.1;  
• Review and documentation of concomitant prescription and non- prescription medications;  
• A problem -oriented physical examination ; only if determined necessary by [CONTACT_10670];  
• Vital signs ( blood pressure, heart rate, respi[INVESTIGATOR_1487], temperature );  
• Pain assess ment  of the treatment area wit h the Numeric Rating S cale ( NRS -11); 
• Photography of the  treatment area and  eligible  lesion s, incorporating a ruler for size 
evaluation;  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808635], Inc.  CONFIDENTIAL  Page 32 of 62 • Subject will return SOR007 ointment tube for dosing compliance ( Section 5.1.10)  and 
study drug accountability ( Section 5.2) purposes;  
• Adverse events review;  
• Subject diary  from Visit [ADDRESS_808636] source documents by a delegated staff.  
• A new Visit [ADDRESS_808637] for daily completion. 
This visit will constitute the End -of-Treatment visit for Group A subjects. All subjects will be 
required to complete a 30 -day safety fol low-up period (including Visits 6 and 7 for Group A and 
Visits 7 and 8 for Group B  in the dose expansion phase ). 
Subjects in the dose expansion phase continuing to an additional 28 days of treatment (or 56 
treatment days) will proceed to Treatment B Visit 5 procedures : 
• Application of SOR007;  
• Adverse events review ; 
• Subject will be supplied with the appropriate number of tubes of SOR007 for treatment 
until the next visit.   
Group B Visit 6 (Day 57 + 2 Days)  
• Subject will self -apply the last dose of SOR007 the evening prior to the visit;  
• Day 57 PK sample collection;  
• Blood samples will be collected for routine hematology and serum chemistry, as per 
Sectio n 6.4.1;  
• Review and documentation of concomitant prescription and non- prescription medications;  
• A problem -oriented physical examination ; only if determined necessary by [CONTACT_10670];  
• Vital signs ( blood pressure, heart rate, respi[INVESTIGATOR_1487], temperature );  
• Pain assess ment  of the treatment area wit h the Numeric Rating S cale (NRS -11); 
• Photography of the  treatment area and  eligible  lesion s, incorporating a ruler for size 
evaluation;  
• Subject will return SOR007 ointment tube for dosing compliance ( Section 5.1.10)  and 
study drug accountability ( Section 5.2) purposes;  
• Adverse events review;  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808638], Inc.  CONFIDENTIAL  Page 33 of 62 • Subject diary  from Visit [ADDRESS_808639] source document s by a delegated staff.  
• A new Visit [ADDRESS_808640] for daily completion. 
This visit will constitute the End -of-Treatment visit for Group B subjects. All subjects will be 
required to complete a 30 -day safety follow -up period (including Visits 7 and 8). 
6.5.4 Follow up  and End -of-Study Evaluation s: Group A   
Visit 6 (Day 43 ± 2 Days)  End -of-Study Evaluations  
• Day 43 PK sample collection at any time during  the visit;   
• Review and documentation of concomitant prescription and non- prescription medications; 
• Problem -oriented physical examination only if determined necessary by [CONTACT_10670];  
• Vital signs ( blood pressure, heart rate, respi[INVESTIGATOR_1487], temperature );  
• Pain assess ment  of the treatment area;  
• Photography of the treatment area and eligible  lesion s, incorporating a ruler for size 
evaluation;  
• Blood samples will be taken for routine hematology and serum chemistry ; 
• Urinalysis by [CONTACT_5230];  
• Adverse events review;  
• Subject diary from Visit [ADDRESS_808641] source documents by a delegated staff.   
Visit 7 (Day 59 + 2 Days)  - Final Visit  
Thirty days following the last study drug application all subjects must complete a final visit. The 
visit may be conducted at the Investigator’s discretion as a clinic/office visit or by [CONTACT_648]. During this visit the site will follow up on any existing adverse events and record any new adverse events. If the visit is conducted in the clinic/office, a physical exam may be conducted, only if 
deemed necessary by [CONTACT_737]. If the visit is conducted by [CONTACT_648], all phone call details 
must be recorded in the subject source.  
6.5.5 Follow up  and End -of-Study Evaluation s: Group B   
Visit 7 (Day 70 ± 2 Day s) End -of-Study Evaluations  
• Day 70 PK sample collection ;  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808642], Inc.  CONFIDENTIAL  Page 34 of 62 • Review and documentation of concomitant prescription and non- prescription medications;  
• Problem -oriented physical examination only  if determined necessary by [CONTACT_10670] ; 
• Vital signs ( blood pressure, heart rate, respi[INVESTIGATOR_1487], temperature );  
• Pain assess ment  of the treatment area;  
• Photography of the treatment area and eligible  lesion s, incorporating a ruler for size 
evaluation;  
• Blood samples will be taken for routine hematology and serum chemistry ; 
• Urinalysis by [CONTACT_5230];  
• Adverse events  review ; 
• Subject diary from Visit [ADDRESS_808643] source documents by a delegated staff.   
Visit 8 (Day 86 + 2 Days)  - Final Visit  
Thirty days following the last study drug application all subjects must complete a final visit. The 
visit may be conducted at the Investigator ’s discretion as a clinic/office visit or by [CONTACT_648]. During 
this visit the site will follow up on any existing adve rse events and record any new adverse 
events. If the visit is conducted in the clinic/office, a physical exam may be conducted, only  if 
deemed necessary  by [CONTACT_737] . If the visit is conducted by [CONTACT_648], a ll phone call details 
must be recorded in the  subject source.  
6.5.[ADDRESS_808644] , from either group is withdrawn they would, at minimum, undergo the End -
of-Study (Visit 6  or 7) evaluations . If a subject is withdrawn at a routine study visit, all evaluations 
that would have been done at that study visit should be completed as well as  all End-of-Study 
evaluation s. If a subject received any study drug application, an additional safety assessment  must 
be completed t hirty days (+ 2 days) following the last study drug application ( see 6.5.4/Visit 7 or 
6.5.5/Visit 8) . 
6.5.[ADDRESS_808645] source  notes/clinic or hospi[INVESTIGATOR_609918]/or evaluations performed will be noted and reviewed. The subject will 
undergo any other evaluations determined necessary by [CONTACT_609948]’s well-being. If the Investigator deems it necessary to perform  additional evaluations outside the 
scope of this study, this information will be documented in the subject source documents and 
collected for study purposes . 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808646], Inc.  CONFIDENTIAL  Page 35 of 62 6.5.8 Schedule of Events Table  1: Treatment  Group A: 28 Days  
Timepoint/Study Visit  Screening   
( < 14 days)  Baseline  Treatment  Follow up  
Visit 1  
(Days -13 to Day 0)  Day 1 /  
Visit 2  Day 8 /  Visit 3  
(+/- 1 d) Day 1 5 / Visit 4  
(+/- 1 d) Day 2 9 / Visit 5  
(+ 2 d) Day 43 / Visit 6  
(+/- 2 d) Day 59 /  
Visit 7 (+ 2 d)  
Informed Consent  X       
History and Demographics1 X       
Inclusion/Exclusion  X X2      
Height and Weight  X       
Physical Examination3 X X X X X X  
Vital Signs4 X X X X X X  
ECOG Performance Status  X       
Hematology and Chemistry  X  X X X X  
Urinalysis  X     X  
Pregnancy Test  X       
Pharmacokinetic (PK) Assay5  X X X X X  
Pain Assessment  X X X X X X  
Tumor Measurements6 X X      
Tumor Assessment7   X X X X  
Photography   X X X X X  
Distribute SOR007 Tube(s)   X X X    
Collect SOR007 Tube(s)    X X X   
SOR007 Application Training7  X X X    
SOR007 Application7  X X X    
Adverse Events8 X X X X X X X10 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808647] study drug application.  
3  A comprehensive physical examination to be completed at the screening visit  only; problem -oriented physical exam to  be completed at all other visits , 
as needed . 
4  Vital signs include: blood pressure, heart rate, respi[INVESTIGATOR_149939].  
5.  PK samples will be collected  24 hours (+/ - 2 hours) post the first study drug application; a t Visits 3 and 4 ( prior to the first daily application ); at Visit 5 
and Visit 6 ( at any time during the v isit).  
6  Cutaneous metastatic lesions will be measured with calipers at Screening to determine eligibility and at Baseline to document  the ‘starting dimensions’ 
if different fr om screening. Eligible lesions will be determined by [CONTACT_39694] (version 1.1) definition of measurable tumors (≥ 10mm in its longest 
diameter).  
[ADDRESS_808648] following training by [CONTACT_12244] r or delegated study staff. 
Assigned SOR007 cohort dose will be applied daily on Day 1 to Day  28.  
9 All adverse events and treatment emergent adverse event (TEAE) determination will start immediately following initiation of s tudy treatment.  
[ADDRESS_808649] AEs and CMs.  
11 The final safety assessment to be performed 30 days (+ 2 days) after last study drug dose application. The decision to conduct the visit in clinic or by 
[CONTACT_609949] . 
 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808650], Inc.  CONFIDENTIAL  Page 37 of 62 6.5.9 Schedule of Events Table  2: Treatment Group B: 56 Days  
Timepoint/Study Visit  Screening   
( < 14 days)  Baseline  Treatment  Follow up  
Visit 1  
(Days -13 - 0) Day 1 /  
Visit 2  Day 8 /   Visit 3  
(+/- 1 d) Day 1 5 / Visit 4  
(+/- 1 d) Day 2 9 / Visit 5  
(+/- 2 d) Day 57 / Visit 6  
(+/- 2 d) Day 70 / Visit 7  
(+/- 2 d) Day 86 / Visit 8   
(+ 2 d)  
Informed Consent  X        
History and Demographics1 X        
Inclusion/Exclusion  X X2       
Height and Weight  X        
Physical Examination3 X X X X X X X  
Vital Signs4 X X X X X X X  
ECOG Performance Status  X        
Hematology and Chemistry  X X X X X X X  
Urinalysis  X      X  
Pregnancy Test  X        
Pharmacokinetic (PK) 
Assay   X5 X X X X X  
Pain Assessment  X X X X X X X  
Tumor Measurements6 X X       
Tumor Assessment7   X X X X X  
Photography   X X X X X X  
Distribute SOR007 Tube(s)   X X X X    
Collect SOR007 Tube(s)    X X X X   
SOR007 Application 
Training8  X X X X    
SOR007 Application8  X X X X    
Adverse Events9 X X X X X X X X11 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808651] study drug application.  
3  A comprehensive physical examination to be completed at the screening visit; problem -oriented physical exam to be completed at all other visits as 
needed;  
4  Vital signs include: blood pressure, heart rate, respi[INVESTIGATOR_149939].  
5.  PK samples will be collected 24 hours (+/-  2 hours) post the first study drug application; at Visits 3, 4 and 5 (prior to the first daily application, at Visits 
6 and 7 at any time during the visit.  
6  Cutaneous metastatic lesions will be measured with calipers at Screening to determine eligibility and at Baseline to document the ‘starting dimensions’ 
if different from screening. Eligible lesions will be determined by [CONTACT_39694] (version 1.1) definition of measurable tumors (≥ 10mm in its longest 
diameter) .  
[ADDRESS_808652] following train ing by [CONTACT_609950]. 
Assigned SOR007 cohort dose will be applied daily on Day 1 to Day 56.  
9 All adverse events and treatment emergent adverse event (TEAE) determination will start immediately following initiation of s tudy tre atment.  
[ADDRESS_808653] AEs and CMs.  
11 The final safety assessment to be performed 30 days (+ 2 days) after last study drug dose app lication. The decision to conduct the visit in clinic or by 
[CONTACT_609949].  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808654] stu dy drug application , or medication changed from baseline 
will be collected and recorded on the  electronic  case repo rt forms  (eCRF).  Following Visit 2/Day 
1, if disease progression requires chemotherapy treatment, any treatment can be administered at the discretion of the Investigator . If a taxane treatment is indicated, the subject will be withdrawn 
from the study (See 6.1.2 , 6.5.5).  
For this protocol, a prescription medication is defined as a medication that can be prescribed only 
by a properly authorized/licensed clinician. Medications and/or treatments to be reported in the eCRF are concomitant prescription medications, over -the-counter medications, and non -
prescription medications.  
6.6.1 Precautionary Medications, Treatments, and Procedures  
No precautionary medications, treatments, or procedures are included in this protocol; they may, however, be administered at the discretion of the Investigator  or the subject’s primary care provider 
or oncologist  unless a prohibited medication (See 6.6.2) ; all medications will be recorded.   
6.6.2 Prohibited Medications, Treatments, and Procedures  
Systemic treatment or treatment to the target area with radiotherapy, intralesional therapy; laser 
therapy surgery other than biopsy , local hyperthermia, levulinic acid, 5- fluorouracil, high 
potency corticosteroids (including systemic steroids), retin oids, diclofenac, hyaluronic acid, 
imiquimod  within the [ADDRESS_808655] lesional 
therapy ( e.g. intralesional injections, laser, hyperthermia, and steroids  to within 2 inches (5 c m) 
of the 50 cm
2 treatment area)  within [ADDRESS_808656] study drug application  or during 
the study . Following Visit 2/Day 1, if disease progression requires taxane chemotherapy 
treatment, the subject will be removed from the study ( i.e.: study drug treatments to be 
discontinued). All early termination assessments (Visit 6 or 7) as well as the [ADDRESS_808657] study drug dose 
application call or visit, per protocol.  
6.6.3 Prophylactic Medications, Treatments, and Procedures  
No specific prophylactic medications ar e required for this study. While prophylaxis is commonly 
administered to subjects receiving intravenous paclitaxel , clinically significant systemic exposu re 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808658] the need, provided these are not 
prohibited medications , treatments  or procedures (see Section  6.6.2) .  
 
7 ASSESSMENT OF SAFETY  
7.1 Specification of Safety Parameters  
Safety assessments being conducted in this study include:  
• Laboratory assessments;  
• Adverse events and TE AE, collected at all study visits from the time of initial dosing;  
• Changes in concomitant medications and;  
• Findings from physical examinations.  
Safety will be reviewed by [CONTACT_609951], and 
details will be confirmed at routine on -site monitoring visits.  
7.1.1 Definition of Adverse Events  (AE) and Adverse Drug Reaction (ADR)  
An AE is any untoward medical occurrence (whether or not considered to have a causal  
relationship to  the study drug)  in a study subject administered the study drug . Therefore, an AE 
can be any  unfavorable and unintended sign (including a clinically significant laboratory finding),  
symptom, or disease temporally associated with the u se of an study drug , whether or not related to 
the study drug . For the purposes of this protocol, all AE  occurring during the study are  considered 
treatment -emergent AE (TEAE ) associated with the use of the product), whether or not the AE is 
determined to be product related.  
According to the FDA Guidance for Industry Adverse Reactions Section of Labeling for Human 
Prescription Drug and Biological Products —  Content and Format (January 2006) , an adverse 
reaction is an undesirable effect, reasonably associated with the use of a drug, that may occur as 
part of the pharmacological action of the drug or may be unpredictable in its occurrence. This definition does not include all adverse events observed during use of a drug, only those for which there is some basis to believe there is a causal relationship between the drug and the occurrence of the adverse event. Adverse reactions may include signs and symptoms, changes in laboratory 
parameters, and changes in other measures of critical body function, such  as vital signs and ECG.  
7.1.2 Definition of Serious Adverse Events  (SAE)  
All AE  must be evaluated as potential serious adverse events (S AE). An SAE is any untoward 
medical occurrence that at any dose:  
• Results in death;  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808659], Inc.  CONFIDENTIAL  Page 41 of 62 • Is life -threatening (i.e., the subject was  at immediate risk of death from the AE as it 
occurred ). This does not include an event that, had it occurred in a more severe form or 
was allowed to con tinue, might have caused death;  
• Requires inpatient hospi[INVESTIGATOR_609919]; 
• Results in persistent or significant disability/incapacity;  
• Is a congenital anomaly/birth defect (in the child of a subject who was exposed to the study 
drug) ; or 
• Is a medically important event or reaction:  
 
Events that do not result in death or hospi[INVESTIGATOR_230647], based on appropriate medical judgment, jeopardize the subject or require intervention to prevent one of the outcomes in the 
definition of SAE listed above, should also be considered S AE. 
7.2 Classification of an Adverse Event  
7.2.1 Severity o f Event  
The Investigator will assess the severity of AE according to the criteria below:  
• Mild: The AE is transient and does not interfere significantly with the subject’s normal 
functioning level. The AE resolves spontaneously or may require minimal therapeutic intervention. 
• Moderate: The AE produces limited functional impairment and may require therapeutic 
intervention. The AE produces no sequelae.  
• Severe: The AE results in significant impairment of function and may lead to temporary 
inability to res ume the subject’s normal life pattern. The AE produces sequelae which 
require prolonged therapeutic intervention.  
• Life Threatening:  The AE results in life -threatening consequences, urgent intervention is 
indicated, urgent operative intervention is indicate d or the patient is at risk of death at the 
time of the event if immediate intervention is not undertaken.   
• Fatal: The AE results in death . 
 
Further, toxicities will be evaluated according to the current NCI CTCAE  (version 4.0)  criteria . 
7.2.[ADDRESS_808660]:  
 
• Definitely related: A clinical event (including laboratory test abnormality) occurring in a 
plausible time relationship to  drug administration, and which cannot be explained by 
[CONTACT_9153]. The response to withdrawal of the drug 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808661], Inc.  CONFIDENTIAL  Page 42 of 62 (de-challenge) should be clinically plausible. The event must be definitively associated 
pharmacologically, using a satisfactory re- challenge procedure, if necessary.  
• Probably related: A clinical event (including laboratory test abnormality) with a 
reasonable time sequence to administration of the drug, unlikely to be attributed to concurrent disease or other drugs or  chemicals, and which follows a clinically reasonable 
response on withdrawal (de -challenge). Re- challenge information is not required to fulfill 
this definition.  
• Possibly related: A clinical event (including laboratory test abnormality) with a reasonable 
time sequence to administration of the drug, but which could also be explained by 
[CONTACT_9153]. Information on drug withdrawal may be 
lacking or unclear.  
• Unlikely to be related : A clinical event  (including laboratory test abnormality) whose  
temporal relationship to drug administration makes a causal relationship improbable (e.g., 
the event did not occur within a reasonable time after administration of the trial medication) 
and in which other drugs or chemicals or underlying  disease provides plausible 
explanations (e.g., the participant’s  clinical condition, other concomitant treatments).  
• Not related: An event for which sufficient information exists to conclude that the etiology 
of the event is unrelated to the study drug . An alternative definitive etiology should be 
documented by [CONTACT_737].  
 Causality will be assessed as follows: 
The Investigators will assign causality at their respective sites during the study. The SMC 
will review the assigned causality for all AE  and S AE prior to database lock. This 
assignment will be included in the study database and final study report. As noted in the FDA Guidance for Industry Adverse Reactions Section of Labeling for Human 
Prescription Drug and Biological Products —  Content and Format , decisions on whether 
there is some basis to believe there is a causal relationship will be based on factors such as: (1) the frequency of reporting, (2) whether the adverse event rate for the drug exceeds the placebo rate, (3) the extent of dose -response, (4) the extent to which the adverse event is 
consistent with the pharmacology of the drug, (5) the timing of the event relative to the time of drug exposure, (6) existence of challenge and de -challenge experience, and (7) 
whether the adverse even t is known to be caused by [CONTACT_609952].  
7.2.3 Expectedness  
Expected adverse reactions are AE  that are common and known to occur for the study agent being 
studied. Expectedness refers to the awareness of AE  previously observed, not on the basis of what 
might b e anticipated from the properties of the study agent.  
An AE or suspected adverse reaction is considered "unexpected" if it is not listed in the Investigator’s Brochure ( IB) or is not listed at the specificity or seve rity that has been observed; 
or is not consistent with the risk information described in the general investigational plan or 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808662], Inc.  CONFIDENTIAL  Page 43 of 62 elsewhere in the protocol, as amended. "Unexpected," as used in this definition, also refers to AE  
or suspected adverse reactions that are mentioned in the IB as occurring with the  class of drugs or 
as anticipated from the pharmacological properties of the drug, but are not specifically mentioned 
as occurring with the particular drug under investigation.  
The Medical Monitor  and sponsor’s Medical Director will be responsible for determining whether 
an AE is expected or unexpected.  
7.[ADDRESS_808663] 30 days after onset , whichever is later . At each study visit, the investigator will 
inquire about the occurrence of AE/S AE since the last visit. Events will be f ollowed for outcome 
until resolution or stabilization.  
7.[ADDRESS_808664] reports several signs or symptoms, which 
represent a single syndrome or diagnosis, the latter should be recorded in the eCRF.  
Information to be collected includes event descript ion, time of onset, clinician’s assessment of 
severity, relationship to study product (assessed only by [CONTACT_8703] a diagnosis), and time of resolution/stabilization of the event. All AE  occurring while on 
study must be documented appropriately regardless of relationship. All AE  will be followed to 
adequate resolution. 
Any medical condition that is present at the time that the participant is screened until just prior to 
the first study drug application will be considered as baseline medical history condition and not reported as an AE . However, if the study participant’s condition deteriorates at any time during 
the study, it will be recorded as an AE.  
Changes in the severity of an AE will be documented to allow an assessme nt of the duration of the 
event at each level of severity to be performed. AE  characterized as intermittent require 
documentation of onset and duration of each epi[INVESTIGATOR_1865]. 
Clinically significant laboratory abnormalities will be recorded as adverse events. Clinically 
significant laboratory abnormalities are those that are changed compared to baseline and require intervention, whether or not they are associated with signs or symptoms.  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808665], Inc.  CONFIDENTIAL  Page 44 of 62 7.4.2 Serious Adverse Event Reporting  
The study clinician will complete a SAE Form within the following timelines: 
• All deaths and immediately life -threatening events, whether related or unrelated, will be 
recorded on the SAE Form and submitted to the S ponsor within 24 hours of site awa reness.  
• Other S AE regardless of relationship, will be submitted to the S ponsor within 72 hours of 
site awareness.  
All S AE will be followed until satisfactory resolution or until the site investigator deems the event 
to be chronic or stable. Other supporting documentation of the event should be provided as s oon 
as possible. The S ponsor will be responsible for notifying FDA of any unexpected fatal or life -
threatening suspected adverse reaction as soon as possible but in no case,  later than 7 calendar 
days after the sponsor's initial receipt of the information . 
All S AE, including death, due to any cause which occurs during this study between the period of 
dose administration and last study visit, whether or not expected and regardless of relationship to 
study drug, must be reported to the Medical Monitor immedia tely upon discovery of the event, 
using the SAE reporting form, scanned and sent by [CONTACT_6968]. Additionally,  the SAE report form may 
also be submitted to the sponsor by [CONTACT_6791]. SAE  reports should be sent to:  
[CONTACT_609971]- Mast  
Medical Monitor      Director, Clinical Trials  
Email: [EMAIL_7840]     Email: [EMAIL_7838]   
Phone: 805- 235-9193      Phone: 281- 685-6092 
Fax: 805- 980-4897      Fax: 805- 980-4897 
 
24-hour Emergency Contacts:   Gere diZerega, MD  or Tony Verco, MD  
     Medical Director   Medical Monitor  
     [PHONE_12627]    [PHONE_12628]  
 The sponsor will advise the Investigator regarding the nature of any further information or 
documentation that is required. The Investigator should provide the following documentation at 
the time of SAE reporting if  available:  
• SAE Report Form;  
• Concomitant and support medication pages;  
• Relevant diagnostic reports;  
• Relevant laboratory reports;  
• Admission Notes;  
• Hospi[INVESTIGATOR_44458] (when available).  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808666] usually attributed to paclitaxel include infusion reactions, vital 
signs, and bone marrow depression. Additionally, systemic toxicity due to paclitaxel exposure 
such as reduction in neutrophils (absolute and relative) and thrombocytopenia  will be monitored  
by [CONTACT_456]. Due to the low total dose administered, very low surface area of cutaneous 
metastases surface exposed  relative to body weight and size , and expected absorption rate of 
SOR007, it is unlikely that detectable and clinically relevant systemic levels of SOR007 will occur . 
7.4.[ADDRESS_808667] one medically approved and highly effective birth control method (low failure rate (i.e. 
< 1% per year when used consistently and correctly) to include hormonal methods, barrier methods, IUD or abstinence. Any contraceptive method or justification for lack of method must 
be recorded in the subject source.  
If any subjec t becomes pregnant during the study, the subjec t must be followed up until birth or  
termination of pregnancy. The pregnancy is to be immediately reported to US Biotest on the 
Pregnancy Report form. The anticipated date of birth or termination of the pregnancy should be 
provided at the time of the initial report. The outcome of the pregnancy should be reported to US Biotest as soon as it is known on the P regnancy Report form . If the pregnancy ends for any reason 
before the anticipated date initially reported the Investigator must notify US Biotest the following 
working day.  
If the outcome of the pregnancy meets any criteria for classification as a SAE (including stillbirth, 
neonatal death, spontaneous abortion, or congenital anomaly - including that in an aborted fetus) 
the Investigator must follow the procedures outlined in prot ocol Section 7.4.2. for reporting S AE. 
Any neonatal death occurring ≤ 30 days after birth will be reported as a SAE.  
7.5 Study Halting Rules  
This study is a Phase 1/ 2 dose escalation study, and dose escalation will be determined following 
review of all safety and tolerability data of a cohort by [CONTACT_609953] .  
The Sponsor is responsible for notifying the FDA of any temporary halts to the study or when a 
study is terminated; the Investigator will be required to notify the IRB accordingly.  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808668], Inc.  CONFIDENTIAL  Page 46 of 62 The severity of toxicity will be classified according to CTCAE criteria  (version 4.0) . Any 
adverse event that is considered related or possibly  related to SOR007 is potentially a DLT. The 
definition of a DLT will be made by [CONTACT_609954] .  
Dose escalation of SOR007 will be halted when ≥ 2 grade 3 AEs (CTCAE  version 4.0) , occur  in 
any single cohort/dose level and are determined to be “probably related” to SOR007 (See Figure 
2). Further enrollment will be temporarily halted until the safety review has been conducted.  The 
Medical Monitor, in conjunction with the SMC will determin e next steps  per the Safety Monitoring 
Plan. The final decision for dose escalation and/or premature study drug discontinuation is the 
responsibility of the Medical Monitor.   
7.[ADDRESS_808669] 3+[ADDRESS_808670] cohort of three subjects commencing treatment with 0.15% SOR007. The SMC  will 
review all available data on a monthly basis and after the last subject in each cohort of three 
subjects co mpletes [ADDRESS_808671] 3 subjects in a cohort, dose 
escalation may proceed. If a single dose limiting toxicity (DLT) is identified in one of three 
subjects in the cohort, a further three subjects will be enrolled at the same dose level. If one or more DLT occur in the three additional subjects enrolled in the cohort, dose escalation will stop and the prior dose level will be  regarded as the Maximum Tolerated Dose (MTD) and taken 
forward into the dose expansion phase. If no further DLT s are identified, dose escalation will 
continue, until either a DLT is identified at a higher dose or the top dose of 2.0% SOR007 is 
reached.  During the dose expansion phase the SMC will review all available data on a monthly 
basis until the study is complete.  
If it is determined that a DLT has been reached, the prior dose level will be defined as the highest dose with an acceptable safety and tolerability level.   
Figure 2. Dose Escalation and Study Stop Algorithm – Step -by-Step Procedure  
Step  Regimen  Outcome  Outcome 2  Next Step  
1 
(n=3)  0.15% BID  2 DLT  STOP STUDY  
1 DLT – add 3 subjects  If 1 further DLT  STOP STUDY  
If no DLT  Go to Step 2 (1% BID)  
0 DLT  Go to Step 2 (1% BID)  
2 
(n=3)  1% BID  2 DLT  Go to Step 4 (0.15% BID)  
1 DLT – add 3 subjects  If 1 further DLT  Go to Step 4 (0.15% BID)  
If no DLT  Go to Step 3 (2% BID)  
0 DLT  Go to Step 3 (2% BID)  
3 
(n=3)  2% BID  2 DLT  Go to Step 5 (1% BID)  
1 DLT – add 3 subjects  If 1 further DLT  Go to Step 5 (1% BID)  
If no DLT  Go to Step 6 (2% BID)  
0 DLT  Go to Step 6 (2% BID)  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808672], Inc.  CONFIDENTIAL  Page 47 of 62 Step  Regimen  Outcome  Outcome 2  Next Step  
4 0.15% BID  ≥ 3 DLT  STOP STUDY  
5 1% BID  ≥ 3 DLT  STOP STUDY  
6 2% BID  ≥ 3 DLT  STOP STUDY  
Dose Limiting Toxicity  will be defined as :  
Non-Hematologic : 
• > Grade 3 non- hematological  toxicity, exclu ding nausea, vomiting, diarrhea;  
• > Grade 3  nausea , vomiting, or diarrhea uncontrolled by [CONTACT_346707]/ 
antidiarrheal th erapy >72 hours;  
• Any toxicity which  in the judgment of the Medical Monitor, Principal Investigator [INVESTIGATOR_609920] a DLT;  
• Hypersensitivity  reactions to SOR007 that cannot be controlled with standard treatment ; 
• New ulceration within the treatment area ; 
• ALT or AST >3x ULN  and total bilirubin >  2x ULN . 
• Any death not clearly due to the underlying disease or extraneous cause . 
Hematologic:  
• > Grade 3  anemia and/or neutropenia;  
• Neutropenic fever;  
• Thrombocytopenia  of any Grade if associated with clinically significant bleeding 
(clinically significant as determined by [CONTACT_737], or results in a transfusion of red 
blood cells.),  
•  Grade 4 thrombocytopenia without bleeding.  
Study Halt  Rules : 
• New ulceration within the treatment area occurring in ≥ 2 of 6 subjects in each dose 
escalating cohort, or ≥ 3 of 9 subjects in the dose expansion cohort .  
• Any Grade 4 dermal toxicity  
• ≥ 3 Grade 3 AE occur ring in the cohort of 9 subjects , and which are determined to be 
“probably related” to SOR007 (in the dose e xpansion phase only) . 
Dose Expansion Phase:  
In the dose expansion phase, additional subjects will be enrolled to reach a maximum of 16 total 
subjects at the dose level determined to be the MTD in the dose escalation phase. Subjects in the  
dose expansion phase will attend the clinic on the same visit days and receive the same evaluations 
as the dose escalation phase above.  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808673] 
entered to the database on a regular basis  (in both dose escalation and dose expansion) , and upon 
completion of the Day [ADDRESS_808674] 
of the trial is in compliance with the curren tly approved protocol/amendment(s), with GCP, and 
with applicable regulatory requirement(s).  
US Biotest monitors, or monitors designated by [CONTACT_609955], will conduct scheduled site visits to 
the investigational centers for the purposes of monitoring the study. The Investigator agrees to allow these monitors, and other authorized sponsor personnel or designees, access to the subject’s 
medical records, Investigator Site F ile (ISF) , eCRF, and any other source documents as needed to 
assure the conduct of the study is within compliance. In addition, the FDA or other government 
agencies may request an inspection following notification to the site. In such an event, the 
Investigator agrees to notify the sponsor immediately of the request, and will allow sponsor and 
inspectors to review records.  
US Biotest will conduct a Site Initiation Visit to provide the Investigator and their staff with a 
comprehensive overview of the protocol and study procedures and to review mutual obligations 
and requirements of regulatory aut horities prior to any subjects being consented. The Investigator 
Site F ile (ISF) or  regulatory file containing essential and non- essential  documentation will be kept 
at the site for reference and inspection. 
Routine monitoring visits will be conducted by [CONTACT_609956], to review and verify all study documentation is properly maintained to include, but not 
limited to: the subject’s source documents, the eCRF, clinical supplies, all investigational prod uct 
receipt, accountability, storage and disposition records are maintained and to assess the continued 
suitability of the investigational site.  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808675] or designee.  
9 STATISTICAL CONSIDERATIONS   
9.1 Statistical and Analytical Plans  
A formal Statistical Analysis Plan (S AP) will be prepared for this trial, and the SAP will be signed 
off prior to study database lock.  
9.2 Statistical Hypotheses  
No formal statistical inference (i.e. “p -values”) will be applied.  The results of this trial will be 
based on descriptive statistics o nly. 
9.[ADDRESS_808676] one dose of 
study drug will be included in the descriptive analysis.  
9.3.1 Missing Data 
Data will be presented as observed and no missing data imputa tion will be performed.   
9.4 Description of Statistical Methods  
9.4.1 General Approach  
The focus of the trial will be on the safety and tolerability of the dose escalated treatments.  The 
general approach will be to highlight any trends that cause concern for the reviewing medical monitoring team (i.e. dose limiting toxicities ( DLT )). 
9.4.2 Analysis of the Primary Efficacy Endpoint(s)  
Not applicable. The primary objective is to evaluate the safety and tolerability as demonstrated by [CONTACT_135503] , changes in laboratory assessment s, physical examination findings and vital signs. 
9.4.3 Analysis of the Secondary Endpoint(s)  
Secondary endpoints will be summarized descriptively.  These will include supportive information to provide context for the dose(s) chosen to move forward for future st udy.   
 
• Objective tumor response, defined as the difference in the sum of the tumor diameter/s 
between baseline and Visit 6; i.e. [ADDRESS_808677] dose in the dose escalation and 
expansion phases depending on dose regimen. Tumor surface area and response will be 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808678], Inc.  CONFIDENTIAL  Page 50 of 62 assessed at all visits. Change in surface area will be assessed using ImageJ freeware 
provided by [CONTACT_18121].  
• Objective Clinical Response is defined as subjects with Complete Clinical Response (CR) + Partial Response (PR), further defined as the  percentage of subject s who achieve 
complete clinical response or partial response [ADDRESS_808679] diameter/s of the target lesion /s [ADDRESS_808680] -treatment 
total diameter divided by [CONTACT_609957].  
• Best overall response is defined as the best response recorded from the start of study treatment until the end of the study i.e. Visit 6/Day 4 3 or Visit 7/ Day 70.  
• The definition of eligible cutaneous tumors is based on the  (version 1.1) definition of 
measurable tumors ( superficial and ≥ 10mm in its longest diameter ). Complete clinical 
response (CR) is defined as absence of any detectable residual disease in the target lesion/s ; 
partial response (PR) as at least a 30% decrease in the sum of the diameters of the target lesion/s compared to baseline (Visit 2); and progressive disease (PD) as at least a 20% increase in the sum of diameters of target lesion/s, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 mm. 
Stable disease (SD) is defined as the sum of target lesion diameters between that defined 
as PR or PD.  
• The app earance of new non -target lesions during participation in this study does NOT 
constitute progressive disease.  
• Change in pain ( NRS -11) score  from baseline to any post -baseline time point that the pain 
scale captures.  
• The concentration of paclitaxel in the systemic circulation post- topi[INVESTIGATOR_59407], will 
be measured by [CONTACT_133008] (PK) sampl ing for Group A Subjects on Days 1 ([ADDRESS_808681] -application) , 8, 15, 29 and 43 or for Group B Subjects Days 1  ([ADDRESS_808682] -
application) , 8, 15, 29, 57 and 70. If some concentration data is above the detectable limit 
and can be reported numerically, this data will be tabulated and graphed for individuals and by [CONTACT_7169].  
9.4.4 Safety Analyses  
[IP_ADDRESS] Adverse Events  
Adverse events ( AE) recor ded during the trial will capture medically relevant changes found 
during the physical exam, and medically relevant changes in vital signs and laboratory analytes found during the course of the trial.  In addition, spontaneously reported or observed events  will 
be reco rded 
Events reported at or after the application of SOR007 will be considered Treatment Emergent 
Adverse Events (TE AE).  All reported events will be listed by [CONTACT_609958], investigator term, MedDRA coded term, date/study day (from initial treatment) for 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808683], Inc.  CONFIDENTIAL  Page 51 of 62 onset and cessation, severity (using the NCIC severity grading), relationship to study medica tion 
and but only the TE AE will be tabulated.  
Safety analysis for dose escalation will be based on the review of the data from the first [ADDRESS_808684] recent version of MedDRA, signed off by [CONTACT_609959] (SOC) and preferred term.  All AE and abnormal laboratory variables will be assessed according to the NCI -CTCAE  (version 4.0)  grading 
system . The number of subjects and number of events reported will be presented in frequency 
tables (overall, by [CONTACT_2236], by [CONTACT_411247]) for each dose cohort.  Adverse events of special interest (e.g., AE leading to study drug discontinuation, SAE, DLT , deaths ) will be 
presented separately.   
[IP_ADDRESS] Laboratory Analytes  
Quantitative laboratory data will be summarized as mean values and change from baseline scores 
(change = baseline -visit) presented by [CONTACT_411248].  For tests with 
normal range s provided, the clinical status and its change from baseline (Normal/High 
Abnormal/Low Abnormal) will be summarized using shift tables for each dose group.  Analytes of particular interest (e.g., hematological tests) may be graphed by [CONTACT_609960]; these special analytes will be confirmed in the SAP.  
[IP_ADDRESS] Vital Signs  
Vital signs (systolic and diastolic blood pressure, heart rate, respi[INVESTIGATOR_609921]) will 
be tabulated and mean raw values and changes from baseline scores (change = baseline- visit) 
where baseline is the last measurement prior to the study drug application, for each treatment group.  
9.4.5 Adherence and Retention Analyses  
All subjects who enter the trial will be accounted for and any reasons for early termination noted – including disease progression and AE.  
9.4.[ADDRESS_808685] listing.  Categorical results will be 
summarized.  
9.4.7 Planned Interim Analyses  
[IP_ADDRESS] Safety  Review  
See Section 7.6. 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808686], Inc.  CONFIDENTIAL  Page 52 of 62 [IP_ADDRESS] Efficacy Review  
Not applicable.  
[IP_ADDRESS] Additional Sub- Group Analyses  
Not applicable.  
9.4.8 Multiple Comparison/Multiplicity  
Not applicable, as no inferential analyses will be employed.  
9.4.9 Tabulation of Individual Response Data  
All data collected in the eCRF will at a minimum be listed; listings will support the tabulated 
data/outcomes.  
9.4.[ADDRESS_808687] been conducted using SOR007, paclitaxel is metabolized by 
[CONTACT_9058] P450 isozymes CYP2C8 and CYP3A4 (Taxol Package Insert). Thus, there is a 
potential for drug interactions with concomitantly administered substrates (e.g., repaglinide and rosiglitazone), inhibitors (e.g., gemfibrozil), and inducers (e.g., rifampin) of CYP2C8. There is 
also the potential for paclitaxel to interact pharmacokinetically with CYP3A4 substrates (e.g., 
midazolam, buspi[INVESTIGATOR_5331], felodipi[INVESTIGATOR_050], lovastatin, eletriptan, sildenafil, simvasta tin, and triazolam), 
inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin), and inducers (e.g., rifampin and carbamazepi[INVESTIGATOR_050]).  
9.5 Safety Monitoring Committee (SMC)  
The Safety Monitoring Committee (SMC) will draft and agree to a Charter which outlines the criteria to be applied to the subjects in the trial as well as the final choice of dose groups to be 
studied further, prior to the first subject being enrolled in the trial. The trial statistician will work 
with the SMC to produce specific data driven reports to support their decision making.  
Subject safety will be the primary driver in all decision making.  
9.6 Sample Size  
As there are no formal inferential statistical analyses planned, the sample size estimates below 
are provided for informational purposes only to help with decision- making around the cohort 
size and the rarity of events that could be detected.  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808688], Inc.  CONFIDENTIAL  Page 53 of 62 Defining the primary  endpoint explicitly requires understanding the primary purpose of the 
study. If, as in this case, the primary purpose of the study is dose -finding, then the incidence of 
DLT  would be an appropriate endpoint. When choosing events that will qualify as DLT , it’s 
important to consider the rarity of  events given the small number of subjects. For example, if a 
particular adverse event is known to occur in only 5% of subjects, there is a 26.5% chance it will 
appear in a particular cohort of 6 subjects, and a 60.3% chance it will occur during the study of 22 subjects. If the event only occurs in 1% of patients, there is only a 6% chance it will appear in 
a given [ADDRESS_808689] cohort, and a 16.5% chance it will be observed in the entire study. So rarity is a 
factor that should be considered when deciding whic h adverse reactions to include as part of the 
endpoint. Estimates were obtained using the “confidence interval for probability of observing a 
rare event” calculation in nQuery 6.01.  
The rationale to expand the final cohort in the Dose Expansion Phase to 16 subjects, from either 3 or 6 subjects, was based on the “reasonable gain” in detection rate that each additional subject would provide in this early phase exploratory trial. The calculations were performed using 
nQuery Advisor 6.01 “confidence interval for probability of observing a rare event”. With 16 
subjects the probability of detecting the 0.1 event rate is 71.8% as well as some probability of detecting much rarer events (11.4% probability of detecting an event with a base rate of 0.01, and 46% probability of detecting an event with a 0.5 base rate).     
9.7 Measures to Minimize Bias  
9.7.1 Enrollment/ Randomization/ Masking Procedures  
Not applicable.  
9.7.2 Evaluation of Success of Blinding  
Not applicable.  
9.7.3 Breaking the Study Blind/ Participant  Code  
Not applicable.  
10 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  
Each participating site will maintain appropriate medical and research records for this trial, in compliance with ICH E6 and regulatory and institutional requirements for the protection of confidentialit y of participants. E ach site will permit authorized representatives of the Sponsor and 
Regulatory A gencies to examine (and when permitted by [CONTACT_1289], to copy) clinical records 
for the purposes of quality assurance reviews, audits, and evaluation of the study safety, progress, and data validity.  
Source data are all information, original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808690] demographics and reason for screen fail  
collected .   
Subjects meeting all inclusion/exclusion criteria will have all data entered in an eCRF.  All data in 
the eCRF must reflect the corresponding source document. Any corrections to entries made on the 
eCRF must be documented in a valid audit trail. Only data required by [CONTACT_609961]. 
The Investigator must maintain adequate and accurate source documents on which the eCRF for 
each subject are based. They will be separate and distinct from the eCRF. These records should include detail ed notes on:  
• The medical history prior to the subject’s involvement in the study;  
• Date of informed consent;  
• The basic identifying information that links the subject’s medical record with the eCRF; 
• The results of all diagnostic tests performed, diagnoses made, therapy provided, and any 
other data on the condition of the subject;  
• The medical condition during the subject’s involvement in the study;  
• All AE ; 
• The subject’s exposure to the study medication;  
• The subject’s exposure to any concomitant therapy;  
• All relevant observations and data on the condition of the subject throughout the trial;  
• Justification for all entries in the subject’s eCRF.  
[ADDRESS_808691] to their accuracy, authenticity, and completeness.  
The EDC application being used in this study is OpenClinica,  an open source application which 
has been installed and validated by [CONTACT_609962]., following SOPs based on the 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808692], Inc.  CONFIDENTIAL  Page 55 of 62 Systems Development Life Cycle (SDLC) methodology. All personnel using the system will be 
trained and the training documented. All changes to the database are recorded in an audit trail. The database will be locked when all open queries have b een addressed, all agreed to data is marked 
as source verified, and the PI [INVESTIGATOR_609922].  
All software applications used in the collection of data will be properly validated following standard computer system validation methods  compl iant with all regulatory requirements  
12 ETHICS/PROTECTION OF HUMAN SUBJECTS  
12.[ADDRESS_808693]  
The study will be conducted in accordance with the ethical principles of the Declaration of Helsinki. The Sponsor and Investigator will comply with their responsibilities as defined in 21 
CFR 312.50- 312.70. 
The investigator will ensure that this study is conducted in full conformity with Regulations for 
the Protection of Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 
CFR Part 56, and/or the ICH E6. 
12.[ADDRESS_808694]  
The protocol, informed consent form(s), recruitment materials, and all participant materials will 
be submitted to the IRB for review and approval , in accordance with local legal requirements. It 
is the respons ibility of the Investigator to assure that all aspects of the IRB review are conducted 
in accordance with current regulations. US Biotest and the Investigator must inform each other in writing that all ethical and legal requirements have been met before th e first subject is enrolled in 
the study. Approval of both the protocol and the consent form must be obtained before any 
participant is enrolled. Any amendment to the protocol will require review and approval by [CONTACT_609963] a t the study  site. All changes to the consent form will be 
IRB approved; a determination will be made by [CONTACT_609964] -consented . 
12.3 Informed Consent Process  
12.3.1 Consent and O ther I nformational D ocuments Provided to P articipant s 
Subjects being considered for participation in this study will be provided an Informed Consent Form (ICF) to read and sign before being permitted to participate. The ICF will describe the study 
agent and any prior findings  from previous studies, it will describe the study procedures including 
the timing of study clinic visits and their responsibilities to adhere to those timelines, any risks 
which may be associated with the study agent or the procedures being carried out in the study, and 
all other items required under 21 CFR part 50.25.  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808695], Inc.  CONFIDENTIAL  Page 56 of 62 Subjects will be required to provide signed consent prior to any study -related procedures being  
carried out. The Investigator is required to document the process for obtaining informed consent 
in the source notes  and according to institutional consenting requirements . 
12.3.2 Consent P rocedures and D ocumentation  
Informed consent is a process that is initiated prior to the patient’s  agreeing to participate in the 
study and continues throughout the study subject’s participation.  Extensive discussion of risks and 
possible benefits of participation will be provided to the patients  and their families. Consent for ms 
will be IRB -approved and the participant will be asked to read and review the document. The 
investigator will explain the research study to the patient  and answer any questions that may arise. 
All patients  will receive a verbal explanation in terms suit ed to their comprehension of the 
purposes, procedures, and potential risks of the study and of their rights as research subject s. 
Patients  will have the opportunity to carefully review the written consent form and ask questions 
prior to signing. The pati ents should have the opportunity to discuss the study with their surrogates  
or think about it prior to agreeing to participate. The subjects  may withdraw consent at any time 
throughout the course of the trial. A copy of the informed consent document will be given to the subjects  for their records. The rights and welfare of the subjects  will be protected by  [CONTACT_411112] . 
The Investigator will obtain informed consent from each subject enrolled in the study, in 
accordance with the U.S. Food and Drug Administration (FDA) regulations [ADDRESS_808696] be 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808697] ’s confidentiality is strictly held in trust by [CONTACT_778], their staff, 
the Sponsor , and their agents. This confidentiality includes the  testing of study subject s’ biological 
samples (and genetic tests  where applicable)  in addition to the ir clinical information relating to 
study participation. Therefore, the study protocol, documentation, data, and all other information 
generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third party without prior written approval of the sponsor.  
The study monitor, authorized representatives of the S ponsor, representatives of the IRB and 
applicable government agencies may inspect al l documents and records required to be maintained 
by [CONTACT_737], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and 
pharmacy records for any study subject . The clinical study site will permit access to such records.  
The s tudy subject ’s contact [CONTACT_21225]. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by [CONTACT_609965].  
Study subject s research data, for purposes of statistical analysis and scientific reporting, will be 
transmitted to and stored at M cDougall Scientific.  This will not include the subject ’s contact [CONTACT_10415]. Individual study subject s and their research data will be identified by a 
unique study identification number. The study data entry and study management systems used by 
[CONTACT_267259] M cDougall Scientific research  staff will be secured and password protected. 
At the end of the study, all study databases will be de -identified and archived at US Biotest.  
All local legal requirements regarding data protection will be enforced. The anonymity of study  
subjects must be maintained to the extent required by [CONTACT_2371]. Throughout documentation collection and evaluation, subjects will be identified on eCRF and other documents submitted to US Biotest  
and M cDougall Scientific  by [CONTACT_73976], and  birth date  (if allowed by [CONTACT_609966]) , and their subject number. S ubjects will be advised that all study findings will be 
stored and handled in strictest confidence, according to legal requirements, but will be informed that authorized research Investigators and agents of the FDA, the NCI, and authorized personnel of US Biotest have the right to inspect their medical records.  
12.4.[ADDRESS_808698] ed in the study. Samples will not be available for purposes other than 
indicated within this protocol, and no genetic testing will be performed.  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808699] access at the site prior to 
shippi[INVESTIGATOR_007] t o the laboratories for analysis/assessment. Samples will be stored using codes assigned 
by [CONTACT_609967].  
Samples will only be retained until analysis is complete, following which samples will be disposed 
of accor ding to the laboratory SOP. No samples will be retained for any future use.  
Data will be kept in password- protected computers. Only Investigators and those delegated on the 
Delegation of Authority Log will have access to the samples and data.  
12.[ADDRESS_808700] not be used on any source documentation.  Source documents will be maintained for rec ording data for each participant enrolled in the study. 
Data reported in the eCRF derived from source documents should be consistent with the source 
documents or the discrepancies should be explained and captured in a progress note and maintained in the pa rticipant’s official electronic study record.  
Clinical data (including AE, concomitant medications, and expected adverse reactions data) and 
clinical laboratory data will be entered into OpenClinica, a [ADDRESS_808701] been addressed, all agreed to data 
is marked as source verified, and the PI [INVESTIGATOR_609922]. 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808702] maintain study documents:  
• For a minimum of two years following the date the marketing application (NDA) is approved 
for the indication for which the drug was investigated for;  
• For a mi nimum of two years following the release date of the final report, if no marketing 
application is to be filed, or if the marketing application is not approved for the indication of 
which the drug was investigated or is discontinued and the FDA has been not ified; or,  
• For a minimum of 15 years after the completion or discontinuation of the study to be filed in 
support of the registration in the European Union.  
• The Investigator, or designee will notify the sponsor in writing if the study records are moved 
or transferred to another responsible individual. 
These documents should be retained for a longer period, however, if required by [CONTACT_427]. 
No records will be destroyed without the written consent of the sponsor, if applicable. It is the responsibilit y of the sponsor to inform the Investigator when these documents no longer need to 
be retained  
13.3 Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol, Good Clinical Practice (GCP), FDA or IRB requirements. The noncompliance may be either on the part of the participant, the Investigator, or the study site staff. As a result of deviations, corrective actions are to be developed by [CONTACT_3483].  
These practices are consistent with ICH E6:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.[ADDRESS_808703] be reported  to the local IRB as per their guidelines. The site PI/study staff 
is responsible for knowing and adhering to their IRB requirements.  
Serious non- compliance on the part of the site, and an inability of the Sponsor to bring the site 
back into compliance, w ill be reported to the FDA in accordance with their requirements.  
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808704], Inc.  CONFIDENTIAL  Page 60 of 62 13.4 Publication and Data Sharing Policy 
By [CONTACT_33351], the Investigator agrees with the use of results of the study for the 
purposes of national and international registration, publication, and information for medical and 
pharmaceutical professionals. If necessary, the authorities will be notified of the Investigator's name, address, qualifications, and extent of involvement. The sponsor will prepare an integrated clinical/statis tical report. Publication/presentation of data is not allowed without explicit 
permission from US Biotest. Submission of data for publication/presentation will be coordinated and approved by [CONTACT_609968].  
The Internatio nal Committee of Medical Journal Editors (ICMJE) member journals have adopted 
a clinical trials registration policy as a condition for publication. The ICMJE defines a clinical trial as any research project that prospectively assigns human subjects to intervention or concurrent 
comparison or control groups to study the cause -and-effect relationship between a medical 
intervention and a health outcome. Medical interventions include drugs, surgical procedures, 
devices, behavioral treatments, process -of-care ch anges, and the like. Health outcomes include any 
biomedical or health -related measures obtained in subjects or participants, including 
pharmacokinetic measures and AE. The ICMJE policy, and the Section [ADDRESS_808705] that is appropriate to their participation in the trial. As 
required by [CONTACT_1622], a Financial Disclosure Form will be completed by [CONTACT_609969] 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808706], Inc.  CONFIDENTIAL  Page 61 of 62 Form FDA 1572 for this study at the site, the original will be filed in the TMF and a copy will 
remain in the site’s regu latory binder.  
[ADDRESS_808707] -party liability insurance coverage in accordance with 
all local legal requirements. This insurance will cover all parties involved in the trial including, 
but not necessarily  limited to, the principal Investigator, clinical trial site, and subjects.  
17 LITERATURE REFERENCES  
Alcaraz I, Cerroni L, Rutten A, Kutzner H, Requena L. Cutaneous metastases from internal malignancies: a clinicopathologic and immunohistochemical review. Am J Dermatopathol. 2012; 
34; 347- 393. 
Cabula C, Campana LG, Grilz G, Galuppo S, Bussone R, De Meo L, Bonadies A, Curatolo P, De 
Laurentiis M, Renne M, Valpi[CONTACT_31806] S, Fabrizio T, Solari N, Guida M, Santoriello A, D’Aiuto M, 
Agresti R. Electrochemotherapy in the treatment of cutaneous metastases from breast cancer: a 
multicenter cohort analysis. Ann Surg Oncol. 2015; 22; S442- S450.  
Campana LG, Testori A, Curatolo P, Quaglino P, Mocellin S, Framarini M, Borgognoni L, Ascierto PA, Mozillo N, Guida M, Bucher S, R otunno R, Marenco F, De Salvo GL, De Paoli A, 
Rossi CR, Bonadies A. Treatment efficacy with electrochemotherapy: a multi- institutional 
prospective observational study on 376 patients with superficial tumors. Eur J Surg Oncol. 2016; 
42(12); 1914- 1923.  
DeVit a VT, Hellman S, Rosenberg SA. (2001). Cancer: Principles and Practice of Oncology 6
th 
Edition . Philadelphia, PA; Lippi[INVESTIGATOR_4431] & Wilkins.  
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey, J, Arbuck S, Gwyther S, Mooney M , Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. 
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). 
European Journal of Cancer. 2009; 45; 228- 247. 
Fernández -Antón Martínez, Parra -Blanco V, Avilés Iz quierdo JA, Suárez Fernández RM. 
Cutaneous metastases of internal tumors. Actas Dermosifiliogr. 2013; 104(10); 841- 853. 
Ma P, Mumper RJ. Paclitaxel nano -delivery systems: a comprehensive review. J Nanomed 
Nanotechnol. 2013; 4(2); 1000164. 
Rowinsky  EK, Eise nhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities 
encountered with paclitaxel (TAXOL). Seminars in Oncology. 1993; 20(4); 1- 15. 
Sideras K, Zahasky KM, Kaur JS. Response of cutaneous metastases from breast cancer to 
capecitabine. Clinical Medicine: Oncology. 2008; 2; 415- 418. 
Phase 1/2 Dose -Rising, Safety, Tolerability and Efficacy Study of Topi[INVESTIGATOR_609897]007 for Cutaneous Me tastases  Version: 7.[ADDRESS_808708], Inc.  CONFIDENTIAL  Page 62 of 62 Spratt DE, Gordon Spratt EA, Wu S, DeRosa A, Lee NY, Lacouture ME, Barker CA. Efficacy of 
skin- directed therapy for cutaneous metastases from advanced cancer: a meta- analysis. Journal of 
Clinical Oncology. 2014; 32(28) ; 3144- 3155.  
 